Orthopaedic Surgery - Chordoma

Basics

Chordoma is a low-grade malignant bone tumor arising from remnants of the embryologic notochord.

It accounts for approximately 1–4% of primary malignant bone tumors and is one of the most important primary malignant tumors involving the axial skeleton, particularly the spine and sacrum.

Anatomic Distribution

Chordomas most commonly arise in the sacrococcygeal region, which accounts for approximately 55% of cases.

Around 30% occur in the skull base, particularly the sphenoid or clival region, while approximately 15% develop within the cervical, thoracic, or lumbar spine.

Delayed Diagnosis

Diagnosis is frequently delayed because symptoms are often nonspecific.

Sacral chordoma may present simply as chronic low back, pelvic, or sacral pain and may therefore be mistaken for much more common degenerative musculoskeletal disorders.

Dedifferentiation

Although conventional chordoma is generally considered a low-grade malignancy, a small proportion of tumors, historically reported at less than 5%, may undergo dedifferentiation into a high-grade spindle-cell sarcoma.

Dedifferentiated chordoma behaves much more aggressively than the conventional form.

General Precautions

One of the most important diagnostic pitfalls is failure to consider sacrococcygeal chordoma in a patient with persistent unexplained low back or sacral pain.

Chronic symptoms that are progressive, atypical, or associated with neurologic, bowel, or bladder dysfunction warrant further investigation.

Epidemiology

Chordoma is extremely rare.

The reported annual incidence is approximately 0.08 cases per 100,000 people.

It most commonly presents in adulthood, with a peak incidence around the fourth to fifth decades of life, although it may occur outside this age range.

Risk Factors

No established environmental or lifestyle risk factors have been identified.

Most cases occur sporadically.

Genetics

No common hereditary predisposition is recognized in the majority of patients.

The disease is generally not associated with a typical familial pattern.

Etiology

Chordoma develops from persistent notochordal remnants within the axial skeleton.

The notochord normally contributes to embryologic development of the spine and largely disappears before birth, but residual cells may persist and later undergo malignant transformation.

Tumor Growth

Chordomas often extend beyond the confines of bone.

Sacral tumors, in particular, may produce a large anterior soft-tissue mass extending into the pelvis.

Because the tumor may become very large before producing obvious symptoms, substantial local destruction can be present by the time of diagnosis.

Associated Conditions

No specific associated systemic disorders are typically present.

Diagnosis

Signs and Symptoms

Symptoms depend on tumor location but are usually slowly progressive and nonspecific.

Sacral lesions commonly produce low back pain, pelvic pain, sacral discomfort, or anal pain.

Difficulty Sitting

Patients with sacrococcygeal tumors may find prolonged sitting increasingly uncomfortable.

Pain may arise from direct pressure on the tumor or involvement of adjacent pelvic structures.

Bowel and Bladder Symptoms

Constipation, urinary disturbance, or other pelvic-organ symptoms may develop as the tumor enlarges.

These findings can result from compression or invasion of adjacent pelvic structures or sacral nerve roots.

Radiculopathy

Tumor extension around neural structures may compress or destroy adjacent nerve roots.

This can produce radicular pain, sensory loss, or motor dysfunction corresponding to the level of involvement.

In sacral chordoma, the S1, S2, and S3 roots are commonly at risk.

Physical Examination

Physical findings are often limited despite substantial tumor size.

There may be little to suggest an underlying bone malignancy on routine examination.

Rectal Examination

Large sacral chordomas frequently extend anteriorly into the pelvis.

A mass may be palpable during rectal examination in approximately half of patients with sufficiently advanced sacral disease.

Imaging

Plain Radiographs

Plain radiographs may appear normal or show only subtle abnormalities.

Findings can include bone destruction, cortical expansion, or a lytic sacral lesion.

Limitations of Radiography

Sacral tumors are particularly easy to miss on plain radiographs because bowel gas and fecal material may obscure the lesion.

A normal radiograph therefore does not exclude chordoma when clinical suspicion remains high.

CT

CT is highly sensitive for demonstrating the bony component of chordoma.

Typical findings include midline osseous destruction and an anterior soft-tissue mass.

Calcification

Scattered internal calcifications may be visible on CT.

These mineralized areas can help characterize the lesion but are not specific to chordoma.

MRI

MRI is the preferred modality for defining the full extent of the tumor and its relationship to surrounding structures.

Chordomas are typically low signal intensity on T1-weighted images and high signal intensity on T2-weighted images.

Contrast-Enhanced MRI

Contrast-enhanced MRI helps delineate the dimensions of the mass and its relationship to the spinal canal, nerve roots, pelvic organs, vessels, and surrounding soft tissues.

This information is essential for operative planning.

Imaging the Entire Sacrum

Sacrococcygeal lesions may lie at the extreme inferior edge of lumbar or pelvic MRI studies.

The tumor can therefore be overlooked if the imaging field does not extend far enough inferiorly.

When sacral chordoma is suspected, imaging should include the entire sacrum and coccyx down to the coccygeal tip.

Nuclear Medicine

Conventional technetium bone scans and PET have historically been less useful than CT and MRI for primary characterization of chordoma.

Cross-sectional imaging remains central to diagnosis, staging, and surveillance.

Differential Diagnosis

Destructive Spinal Lesions

Important alternative diagnoses include metastatic bone disease, multiple myeloma, and lymphoma, all of which can produce destructive lesions of the spine or sacrum.

Sacral Tumors

Chondrosarcoma and giant cell tumor may also arise in the sacrum.

Both can produce bone destruction, soft-tissue extension, and in some cases mineralization, making differentiation from chordoma necessary.

Chondrosarcoma

Chondrosarcoma may resemble chordoma radiographically, particularly when it occurs in the pelvis or sacrum.

Tumor location, pattern of calcification, MRI appearance, and histology help distinguish the two lesions.

Treatment

General Principles

The primary treatment for chordoma is complete surgical removal whenever technically feasible.

Because local recurrence strongly influences survival, achieving adequate margins is critical.

Wide En Bloc Resection

The preferred operative strategy is wide en bloc resection with negative surgical margins.

The tumor is removed as a single specimen together with a surrounding margin of uninvolved tissue when anatomy permits.

Importance of Surgical Margins

Incomplete excision or tumor contamination during surgery substantially increases the risk of local recurrence.

Unfortunately, chordomas often lie immediately adjacent to major nerves, blood vessels, bowel, bladder, or spinal structures, making wide margins difficult to achieve.

Chemotherapy

Conventional chemotherapy has little established role in the routine treatment of classic chordoma.

The relatively indolent biology of the tumor and limited chemosensitivity make surgery and local control the major therapeutic priorities.

Radiotherapy

High-dose radiation, particularly proton-beam or other conformal particle-based radiotherapy, may be considered in selected patients.

It can be used when surgical margins are limited, the tumor is unresectable, or as part of a combined treatment strategy.

Follow-Up

Prognosis

Chordoma has a prolonged but potentially aggressive natural history.

Historical series report a median survival of approximately 6.3 years.

Five-year survival has been reported in the range of approximately 50–67%, while 10-year survival has ranged from roughly 28–46%.

Metastatic Risk

The risk of distant metastasis has historically been estimated at approximately 10–40%.

Common metastatic sites include the lungs, bone, liver, and lymph nodes.

Importance of Local Recurrence

Chordoma is unusual among low-grade tumors because local recurrence can itself be a major cause of mortality.

Repeated local growth can progressively involve vital neural, vascular, gastrointestinal, and genitourinary structures.

Relationship Between Recurrence and Survival

Local recurrence is associated with poorer survival.

The best chance for durable control therefore comes from achieving adequate surgical margins during the initial operation whenever possible.

Complications

Wound-Healing Problems

Wound complications are common after major sacral resections.

Historical series have reported wound-healing problems in as many as 45% of patients.

Large incisions, dead space, radiation, extensive soft-tissue dissection, and contamination risk may all contribute.

Injury to Pelvic Structures

Sacral chordoma surgery may place important anterior pelvic structures at risk.

Potential injuries include damage to the iliac vessels, rectum, bladder, ureters, and other pelvic organs.

Sacral Nerve-Root Sacrifice

The functional consequences of surgery depend heavily on which sacral nerve roots must be sacrificed to achieve tumor clearance.

Higher-level bilateral sacrifice produces more severe neurologic deficits.

Bilateral S1 Sacrifice

Sacrifice of both S1 nerve roots, as may occur with total sacrectomy, can result in major lower-extremity motor and sensory deficits together with loss of bowel and bladder function.

Bilateral S2 Sacrifice

Historical data indicate that bilateral S2 root sacrifice is associated with an extremely high likelihood of bowel and bladder dysfunction.

Some patients may require permanent diversion procedures.

Bilateral S3 Sacrifice

Bilateral S3 sacrifice carries a substantial risk of bowel and bladder dysfunction.

Historical series have reported bowel dysfunction in approximately 60% and bladder dysfunction in approximately 75% of such patients.

Bilateral S4 Sacrifice

Sacrifice limited to both S4 roots is associated with a lower risk of bowel dysfunction, although bladder disturbance may still occur.

Historical series reported minimal bowel dysfunction but bladder dysfunction in approximately 31% of patients.

Sexual Dysfunction

Loss of sacral nerve function may also produce sexual dysfunction, depending on the level and extent of nerve-root sacrifice.

Spinopelvic Instability

Major sacral resections can disrupt continuity between the spine and pelvis.

This may produce spinopelvic instability or discontinuity and can require complex reconstruction.

Sacral Insufficiency Fracture

Remaining sacral or pelvic bone may be vulnerable to insufficiency fracture following extensive resection.

Mechanical reconstruction may be required when stability is compromised.

Patient Monitoring

Long-Term Surveillance

Patients require lifelong surveillance because chordoma can recur many years after initial treatment.

Follow-up commonly includes CT or MRI of the operative region once or twice each year, with intervals individualized according to recurrence risk and prior treatment.

Surveillance for Metastases

Imaging should also assess for distant metastatic disease, particularly involving the lungs.

Long-term chest surveillance is therefore commonly incorporated into follow-up.

Clinical Monitoring

Follow-up should assess for new pain, neurologic symptoms, bowel or bladder dysfunction, changes in sitting tolerance, and evidence of wound or reconstructive complications.

Any new or progressive symptom should prompt timely imaging because recurrent disease may initially be subtle.

Orthopaedic Surgery - Chondrosarcoma

Basics

Chondrosarcoma is a primary malignant bone tumor composed of neoplastic cartilage-forming cells within a cartilaginous matrix.

It most commonly involves the pelvis, proximal femur, region around the knee, and spine, although other skeletal sites may also be affected.

Its biologic behavior varies widely depending on histologic subtype and grade.

Tumor Grade and Metastatic Risk

Low-grade, or grade 1, chondrosarcoma has a relatively low metastatic potential, generally less than approximately 5%.

Intermediate-grade, or grade 2, disease carries a higher metastatic risk, commonly around 20–30%.

High-grade or dedifferentiated tumors have a much more aggressive course, with metastatic rates that may approach or exceed 70%.

Mesenchymal chondrosarcoma is also highly aggressive, with a metastatic risk greater than 50%.

Epidemiology

Chondrosarcoma accounts for approximately 20% of primary malignant bone tumors and occurs about half as frequently as osteosarcoma.

It is predominantly a disease of older adults, most often presenting in the sixth through eighth decades of life.

Risk Factors

Important predisposing conditions include hereditary multiple exostoses, Ollier disease, and Maffucci syndrome.

These disorders increase the likelihood of malignant transformation in pre-existing cartilaginous lesions.

Genetics

The genetic basis of chondrosarcoma is heterogeneous and incompletely understood.

Abnormalities involving several chromosomes have been described, including chromosomes 2–11, 14, 15, and 21.

EXT Mutations

Patients with hereditary multiple exostoses caused by an EXT1 mutation appear to have a greater risk of malignant transformation than patients with EXT2 or EXT3 abnormalities.

Myxoid Chondrosarcoma Genetics

Myxoid variants have been associated with a characteristic chromosomal translocation involving chromosomes 9 and 22.

Etiology

Most chondrosarcomas arise de novo, meaning they develop as primary malignant tumors without a known pre-existing lesion.

Others are secondary tumors that develop through malignant transformation of a previously benign cartilage lesion.

Secondary Chondrosarcoma

Secondary chondrosarcoma may arise from a pre-existing osteochondroma or enchondroma.

This is particularly important in patients with hereditary multiple exostoses, Ollier disease, or Maffucci syndrome.

When malignant transformation occurs in these settings, the resulting tumor is often initially low grade.

Dedifferentiated Chondrosarcoma

Dedifferentiated chondrosarcoma accounts for approximately 10% of cases.

It contains a conventional cartilaginous tumor adjacent to a highly malignant noncartilaginous component.

This is one of the most aggressive forms of chondrosarcoma and carries a poor prognosis.

Associated Conditions

Chondrosarcoma is associated particularly with disorders that produce multiple exostoses or enchondromatosis.

Recognition of these underlying conditions is important because changes in pain, lesion size, or imaging appearance may indicate malignant transformation.

Diagnosis

Signs and Symptoms

The typical presentation is deep, gradually progressive pain.

Symptoms may be present for months or even years because many chondrosarcomas grow relatively slowly.

Pain Characteristics

Pain may be worse at night and may persist despite rest.

Unlike many benign musculoskeletal conditions, the discomfort often becomes progressively more constant.

Analgesics or NSAIDs may provide partial relief but usually do not eliminate the symptoms.

Soft-Tissue Mass

With longstanding disease or cortical breakthrough, a palpable soft-tissue mass may develop.

This suggests extension of the tumor beyond the confines of the bone.

History

A high index of suspicion is appropriate when an adult with a known cartilaginous lesion develops new pain, night pain, progressive enlargement, or pain that is no longer relieved by rest.

These features are particularly concerning for malignant transformation.

Physical Examination

The examination is generally nonspecific.

Patients may have tenderness with deep palpation or, in more advanced disease, a palpable soft-tissue mass.

Joint motion may be limited if the tumor is large or located near an articulation.

Laboratory Tests

Routine serum tests are generally not diagnostic.

There are no specific blood markers that reliably establish the diagnosis of chondrosarcoma.

Imaging

Plain Radiographs

Standard AP and lateral radiographs are often highly suggestive of the diagnosis.

The tumor usually appears as an intramedullary lesion containing stippled, ring-like, or arc-shaped calcifications within a cartilaginous matrix.

Cortical Changes

More aggressive lesions may produce substantial cortical abnormalities.

These can include cortical erosion, thickening, expansion, endosteal scalloping, and frank bone destruction.

Chest Imaging

Because chondrosarcoma can metastasize, particularly to the lungs, staging commonly includes chest imaging.

Chest radiographs or, more commonly, CT of the chest may be obtained to evaluate for pulmonary metastases.

MRI

MRI of the affected region is useful for defining the intramedullary extent, cortical involvement, soft-tissue extension, neurovascular relationships, and relationship to nearby joints.

It is also valuable for planning the biopsy approach and surgical resection margins.

Biopsy Planning

The biopsy should be planned carefully because the biopsy tract must usually be removed during definitive tumor resection.

Whenever possible, biopsy planning should be coordinated with the surgeon who will perform the definitive oncologic procedure.

Pathological Findings

Histologic distinction between a benign enchondroma and a well-differentiated low-grade chondrosarcoma can be difficult.

For this reason, pathologic interpretation must be correlated closely with the clinical and radiographic findings.

Trabecular Permeation

A characteristic malignant feature is permeation of pre-existing trabecular bone by the cartilaginous tumor.

This supports an infiltrative rather than expansile benign growth pattern.

Chondroid Matrix

The tumor contains malignant cartilage-producing cells within a chondroid matrix.

Lobulated growth is common.

Cellular Features

Histologic findings may include binucleated chondrocytes, increased cellularity, nuclear atypia, and progressive anaplasia with increasing tumor grade.

Histologic Grading

Conventional chondrosarcomas are usually graded from 1 through 3 according to cellularity, nuclear atypia, mitotic activity, and degree of anaplasia.

Higher grade correlates with a greater risk of metastasis and poorer survival.

Differential Diagnosis

The principal differential diagnoses include enchondroma and bone infarction.

Distinguishing a low-grade chondrosarcoma from an enchondroma can be particularly difficult and often requires integration of symptoms, imaging, and histology.

Treatment

General Measures

Surgery is the mainstay of treatment for conventional chondrosarcoma.

The goal is complete tumor removal with an adequate oncologic margin, thereby minimizing the risk of local recurrence.

Role of Chemotherapy and Radiotherapy

Conventional chondrosarcoma is relatively resistant to both chemotherapy and radiotherapy.

These modalities therefore have a limited role in routine treatment, although selected aggressive subtypes or metastatic disease may be managed differently.

Wide Resection

A wide resection removes the entire tumor together with a surrounding cuff of normal tissue.

This is the standard surgical principle for most intermediate- and high-grade lesions.

Low-Grade Disease

Low-grade lesions may be managed with appropriately selected surgical excision and close radiographic surveillance.

Follow-up commonly includes serial imaging at approximately 6-month intervals during the early surveillance period.

Intermediate- and High-Grade Disease

Patients with grade 2 or 3 chondrosarcoma require more intensive metastatic surveillance.

CT imaging of the chest is commonly performed at regular intervals because the lungs are the most frequent site of metastasis.

Long-Term Surveillance

After approximately 5 years without evidence of disease, follow-up intervals may be increased.

However, long-term surveillance remains important because some chondrosarcomas can recur late.

Physical Therapy

Physical therapy is used after surgery to restore range of motion, strength, gait, and functional independence.

The specific program depends on tumor location and the type of reconstruction performed.

Medication

There is no established medication that reliably treats localized conventional chondrosarcoma.

Patients who develop metastatic disease may receive systemic therapy, but conventional chemotherapy has historically shown limited and inconsistent benefit.

Surgery

Wide resection requires removal of all involved bone and soft tissue while maintaining an adequate margin around the tumor.

The resulting defect may require substantial reconstruction.

Reconstruction

Limb reconstruction can be performed using an allograft, custom prosthesis, modular tumor prosthesis, or other reconstructive technique depending on the site and extent of resection.

Soft-Tissue Reconstruction

Muscle flaps or other reconstructive soft-tissue procedures may be required to cover large defects and protect implants or exposed structures.

Follow-Up

Close postoperative surveillance is required to detect local recurrence, metastasis, or failure of reconstruction.

The intensity of follow-up depends on tumor grade and time since treatment.

Prognosis

Prognosis is strongly determined by histologic grade and subtype.

Low-grade conventional chondrosarcoma generally has an excellent prognosis.

Grade 1 Prognosis

Grade 1 tumors have a metastatic risk of less than approximately 5% and usually have very favorable long-term outcomes when adequately resected.

Grade 2 Prognosis

Grade 2 tumors have a higher metastatic potential, generally below approximately 30%, but overall prognosis remains substantially better than for high-grade disease.

High-Grade and Dedifferentiated Disease

Grades 3 and dedifferentiated tumors carry a poor prognosis because of their high metastatic potential.

Metastatic rates may exceed 70%.

Dedifferentiated Chondrosarcoma Prognosis

Dedifferentiated chondrosarcoma is among the most aggressive subtypes.

Historical series have reported very low long-term survival, with rapid progression once metastatic disease develops.

Mesenchymal Chondrosarcoma

Mesenchymal chondrosarcoma also carries a relatively poor prognosis because of its aggressive behavior and high metastatic potential.

Complications

Important complications include local recurrence, metastatic disease, and failure of reconstruction.

The risk of recurrence rises when surgical margins are inadequate or the tumor is high grade.

Local Recurrence

Local recurrence may result from incomplete resection or microscopic residual disease.

Recurrent tumors can be more difficult to treat and may require additional wide resection or amputation in selected cases.

Metastases

Metastatic spread occurs mainly in intermediate- and high-grade tumors.

The lungs are the most common site, although other organs and bones may also be involved.

Reconstruction Failure

Large oncologic reconstructions can fail because of infection, mechanical loosening, fracture, nonunion, implant failure, or soft-tissue complications.

These problems may require revision surgery.

Patient Monitoring

Patients should initially be reviewed frequently, often at approximately 1–3-month intervals during rehabilitation, depending on the extent of surgery and tumor grade.

Subsequent surveillance should monitor the surgical site, reconstruction, local recurrence, and pulmonary metastases, with imaging intervals adjusted according to oncologic risk.

Orthopaedic Surgery - Chondroblastoma

Basics

Chondroblastoma is a benign bone tumor of cartilaginous origin that characteristically arises in the epiphysis of skeletally immature patients.

It most often develops in the epiphyses of long bones, particularly around major joints.

The proximal humerus is the most commonly involved site, followed by the proximal tibia and femur.

Synonyms

Chondroblastoma of the proximal humeral epiphysis has historically been referred to as a Codman tumor.

Another older term is epiphyseal chondromatous giant cell tumor.

Epidemiology

Chondroblastoma has a mild male predominance, with males affected approximately twice as often as females.

It occurs mainly in adolescents and young adults whose physes are still open or have only recently closed.

Incidence

Chondroblastoma is uncommon.

In large tumor series, it has accounted for approximately 1% of all skeletal neoplasms.

Risk Factors

No specific environmental, developmental, or lifestyle risk factors have been identified.

Genetics

No well-established hereditary predisposition has traditionally been recognized for chondroblastoma.

The tumor is generally considered sporadic.

Etiology

The precise cause remains uncertain.

The neoplastic cells are believed to arise from cartilage-producing precursor cells, or chondroblasts.

Some pathologic similarities exist between chondroblastoma and chondromyxoid fibroma, although they are distinct tumors.

Associated Conditions

Chondroblastomas may contain areas resembling an aneurysmal bone cyst (ABC).

These secondary aneurysmal changes can influence the radiographic appearance and may be associated with a greater risk of recurrence.

Diagnosis

Signs and Symptoms

The most common complaint is persistent mild to moderate pain near the involved joint.

Symptoms often develop gradually and may persist for months or even years before diagnosis.

Joint Stiffness

Because the tumor develops close to an articular surface, patients frequently experience stiffness and loss of motion in the adjacent joint.

Joint Effusion

An effusion may develop in the nearby joint.

This can make the presentation resemble an intra-articular or inflammatory disorder rather than a primary bone lesion.

Local Swelling

Visible or palpable swelling is uncommon.

The tumor usually remains contained within the bone unless it becomes unusually large or extends beyond the cortex.

Physical Examination

Examination may demonstrate a joint effusion and reduced range of motion.

A palpable soft-tissue mass is unusual.

Direct joint-line tenderness is also generally not a prominent feature.

Laboratory Tests

Routine laboratory investigations are usually normal.

Blood tests generally do not assist in establishing the diagnosis.

The erythrocyte sedimentation rate is typically normal, helping distinguish the lesion from some infectious or inflammatory conditions.

Imaging

Plain Radiographs

The classic radiographic appearance is a well-defined lytic lesion within the epiphysis.

The lesion usually has a thin surrounding rim of sclerosis.

Sclerotic Rim

The presence of a narrow sclerotic border is consistent with the relatively slow-growing and benign nature of the tumor.

The lesion may nevertheless enlarge sufficiently to expand or deform the surrounding bone.

Calcification

Small punctate calcifications may occasionally be visible within the lesion.

These reflect mineralization of the cartilaginous matrix.

Role of Radiographs

In a typical young patient with an epiphyseal lesion and characteristic symptoms, the combination of clinical history and plain radiographs may strongly suggest the diagnosis.

Definitive diagnosis, however, depends on histologic evaluation.

MRI

MRI is useful when plain radiographs are not definitive or when the full extent of the lesion must be determined.

The lesion generally has a well-demarcated margin on MRI.

Peritumoral Edema

Surrounding bone marrow and soft-tissue edema are commonly seen on MRI.

This edema can sometimes appear disproportionately extensive compared with the relatively small size of the benign tumor.

Pathological Findings

Histologic confirmation requires identification of characteristic chondroblasts.

These are small round or polygonal cells containing round or oval nuclei.

Chondroblast Appearance

Chondroblasts are often described as relatively plump cells, sometimes likened to the appearance of fried eggs on microscopy.

Chicken-Wire Calcification

One of the classic histologic features is fine calcification extending in a lattice-like pattern around individual chondroblasts.

This is referred to as “chicken-wire” calcification and is strongly associated with chondroblastoma.

Giant Cells

Multinucleated giant cells are commonly scattered throughout the tumor.

Their presence can create histologic resemblance to a giant cell tumor, particularly if the epiphyseal location is not considered.

Aneurysmal Bone Cyst Change

Secondary areas of aneurysmal bone cyst formation may also be present.

These regions contain blood-filled spaces and may contribute to expansion of the lesion.

Differential Diagnosis

Important differential diagnoses include enchondroma, giant cell tumor, osteomyelitis, and fibrous dysplasia.

Age, skeletal maturity, epiphyseal location, radiographic appearance, and histology help distinguish these conditions.

Giant Cell Tumor

Giant cell tumor is an especially important differential diagnosis because both lesions can involve the epiphysis and contain numerous giant cells.

Giant cell tumor typically occurs in skeletally mature patients, whereas chondroblastoma more commonly arises before or around skeletal maturity.

Osteomyelitis

Subacute osteomyelitis can occasionally mimic a well-defined lytic lesion.

Clinical evidence of infection, inflammatory markers, MRI findings, and tissue sampling may help differentiate infection from tumor.

Treatment

General Measures

Operative treatment is generally recommended because continued tumor growth can progressively damage the epiphysis and adjacent articular surface.

The aim is complete local removal while preserving the nearby joint whenever possible.

Surgical Challenges

Treatment may be technically difficult because chondroblastomas often lie immediately beneath the articular surface.

The surgeon must remove the tumor while minimizing damage to the joint cartilage, physis, and surrounding subchondral bone.

Bone Grafting

After removal of the lesion, the residual bone defect is commonly filled with bone graft or another suitable bone-defect substitute.

This provides structural support and promotes healing.

Activity

Pathologic fracture is not usually a major concern with typical chondroblastoma.

Therefore, strict activity restrictions are generally unnecessary unless symptoms, lesion size, postoperative status, or individual anatomy warrant protection.

Physical Therapy

Physical therapy may be useful after surgery to restore joint range of motion, strength, and function.

This is particularly important when preoperative stiffness or postoperative immobilization has limited movement.

Surgery

Because chondroblastoma is a benign tumor, local surgical treatment is usually adequate.

The standard procedure consists of thorough intralesional curettage followed by filling of the resulting defect.

Curettage

The tumor is removed by carefully curetting the lesion from the surrounding bone.

Meticulous removal is important because residual tumor increases the likelihood of recurrence.

Joint Preservation

When the lesion lies directly beneath the articular surface, surgery should preserve as much subchondral bone and cartilage as possible.

Damage to the joint surface may contribute to later stiffness or degenerative change.

Follow-Up

Long-term surveillance is important because recurrence is not uncommon.

Clinical evaluation should assess for recurrent pain, loss of motion, or new joint symptoms.

Prognosis

Overall prognosis is favorable because chondroblastoma is benign.

However, local recurrence remains an important concern.

Recurrence

The recurrence rate for conventional chondroblastoma has been reported at approximately 20% within 3 years.

Recurrence is more likely when the lesion contains substantial secondary aneurysmal bone cyst change.

Complications

The principal complications are local recurrence and joint stiffness.

Joint stiffness may result from the tumor itself, prolonged symptoms, surgical exposure, or postoperative scar formation.

Patient Monitoring

Because recurrence most often develops during the first several years after treatment, serial imaging is recommended.

Radiographs are commonly repeated approximately every 6–12 months for the first 2 years after excision.

Persistent or recurrent pain should prompt earlier reassessment and additional imaging.

Orthopaedic Surgery - Charcot–Marie–Tooth Disease (Hereditary Sensorimotor Neuropathy)

Basics

Charcot–Marie–Tooth disease (CMT) is the most common inherited motor and sensory peripheral neuropathy.

It represents the final common clinical manifestation of numerous genetic abnormalities, involving more than 80 recognized genes, that impair normal peripheral nerve signaling.

The disorder typically progresses in a distal-to-proximal pattern. Distal lower-extremity muscle wasting and weakness develop first, often resulting in cavovarus foot deformity. In some patients, weakness later involves the upper extremities.

Classification

Several major clinical and genetic forms of CMT are recognized.

The five commonly described groups are Type I, Type II, Type III, Type IV, and X-linked CMT.

Type I CMT

Type I is the hypertrophic demyelinating form and accounts for approximately half of affected patients.

The peripheral nerves become thickened because of abnormal myelin formation and repeated demyelination.

Loss of normal myelin causes marked slowing of peripheral nerve conduction.

Type II CMT

Type II is predominantly an axonal form of the disease.

Axonal degeneration produces weakness and sensory abnormalities, while the myelin sheath is relatively preserved.

Nerve conduction velocities are therefore usually only mildly reduced compared with the marked slowing seen in demyelinating disease.

Reflexes may remain relatively preserved.

Type III CMT

Type III, traditionally called Dejerine–Sottas disease, is characterized by marked segmental demyelination.

It is generally a more severe neuropathy and may present earlier than the common forms of CMT.

Type IV CMT

Type IV consists of forms inherited in an autosomal recessive pattern.

The severity and clinical manifestations vary according to the specific genetic abnormality.

X-Linked CMT

CMT-X is inherited through the X chromosome and accounts for approximately 10% of cases.

The severity of disease may differ according to the specific mutation and sex of the affected patient.

Genetics

CMT is genetically heterogeneous.

A particularly important abnormality in common demyelinating forms involves the gene encoding peripheral myelin protein 22-kDa (PMP22).

Other CMT subtypes result from mutations affecting peripheral nerve myelin, axonal structure, intracellular transport, or other components of nerve function.

Inheritance Patterns

Autosomal dominant inheritance with variable penetrance occurs in many forms of Types I, II, and III.

Type IV follows an autosomal recessive pattern.

CMT-X is inherited through the X chromosome.

A detailed family history is therefore an important part of the diagnostic evaluation.

Pathophysiology

Muscle weakness generally progresses from the distal extremities proximally.

In the lower leg, the tibialis anterior and peroneus brevis are commonly affected early.

Selective weakness of these muscles produces characteristic imbalance around the foot and ankle and contributes to development of cavovarus deformity.

Development of Cavus

Weakness of the tibialis anterior allows the peroneus longus to act relatively unopposed.

The peroneus longus plantarflexes the first ray, producing a plantarflexed first metatarsal and contributing to elevation of the medial longitudinal arch.

Development of Hindfoot Varus

Weakness of the peroneus brevis allows the posterior tibialis to dominate.

The resulting inversion force drives the hindfoot into varus.

Toe Clawing

Weakness of the intrinsic muscles and lumbricals allows the long flexor and extensor tendons to overpower the intrinsic musculature.

This imbalance leads to the characteristic clawing of the toes.

Dynamic Hindfoot Inversion

Plantarflexion of the first metatarsal can dynamically force the hindfoot into inversion during weight-bearing.

This mechanism is responsible for a forefoot-driven cavovarus deformity in many patients.

Progressive Rigidity

As the deformity persists, soft-tissue contracture and bony remodeling progressively reduce foot flexibility.

The foot becomes increasingly rigid, with impaired shock absorption and abnormal loading through the hindfoot and midfoot.

Arthritis

Longstanding malalignment and abnormal joint loading may eventually produce degenerative arthritis.

The subtalar, midfoot, and ankle joints may become painful and stiff.

Ankle Instability

Persistent hindfoot varus repeatedly stresses the lateral ankle ligaments.

Over time, ligament attenuation may lead to recurrent ankle sprains and chronic lateral ankle instability.

Associated Conditions

CMT may be associated with musculoskeletal abnormalities outside the foot.

Important associated conditions include scoliosis and developmental dysplasia of the hip.

Scoliosis

Approximately 30% of patients may develop scoliosis.

A proportion of these patients have left thoracic curves, and significant thoracic kyphosis may also be present.

Hip Dysplasia

Developmental dysplasia of the hip occurs in approximately 6–8% of patients.

Hip motion, particularly abduction, should therefore be examined routinely.

Diagnosis

Signs and Symptoms

Patients commonly become symptomatic between approximately 10 and 20 years of age.

Typical presentations include a high medial arch, reduced endurance, decreased coordination, recurrent ankle instability, or a characteristic steppage gait.

Footwear Problems

Progressive cavovarus alignment produces uneven plantar loading.

Shoes may wear out rapidly and asymmetrically, especially along the lateral border.

Muscle Weakness Pattern

Weakness generally appears first in the ankle evertors and dorsiflexors.

The plantarflexors and invertors are typically affected later.

This imbalance contributes substantially to cavus and hindfoot varus.

Sensory Changes

Sensation and proprioception may be diminished.

Reduced proprioceptive input can worsen balance, gait control, and ankle instability.

Steppage Gait

Foot-drop weakness can produce a steppage gait.

The patient excessively flexes the hip and knee during the swing phase so that the toes clear the floor.

Circumduction Gait

Some patients compensate by swinging the affected limb outward in a circumduction pattern during the swing phase.

History

A detailed family history should identify relatives with high arches, claw toes, similar gait abnormalities, distal weakness, or a known diagnosis of CMT.

The rate of progression of weakness and deformity should also be documented.

Ankle Instability History

Patients should be questioned about repeated ankle sprains, giving-way episodes, or feelings of instability.

These symptoms may indicate chronic lateral ligament insufficiency caused by cavovarus alignment.

Pain History

Pain should be localized carefully.

Common symptomatic areas include the lateral ankle, plantar forefoot, midfoot, and sites of callus formation.

Physical Examination

The examination should assess muscle bulk, strength, sensation, foot alignment, deformity flexibility, gait, hip motion, spinal alignment, and upper-extremity involvement.

Calf Atrophy

Distal lower-extremity muscle wasting commonly produces visible calf atrophy.

Muscle Strength

The strength of all major foot and ankle muscle groups should be recorded and followed over time.

Particular attention should be given to dorsiflexion, eversion, inversion, and plantarflexion.

Sensory Examination

Sensation should be assessed, including light touch, proprioception, and protective sensation.

Reduced protective sensation increases the risk of pressure injury from abnormal foot loading.

Hindfoot Varus

The patient should be examined standing and at rest for the presence of hindfoot varus.

The severity of hindfoot varus is closely related to functional impairment, ankle instability, and lateral overload.

Coleman Block Test

The Coleman block test helps distinguish flexible from fixed hindfoot varus.

The patient stands with the heel and lateral border of the foot supported while the first ray hangs freely beyond the edge of the block.

If the heel corrects toward neutral, the hindfoot remains flexible and the varus is largely driven by the plantarflexed first ray.

Passive Hindfoot Correction

Manual correction of hindfoot varus should also be assessed.

A rigid deformity is more likely to require bony correction rather than soft-tissue procedures alone.

Lateral Ankle Ligaments

The lateral ankle ligaments should be examined for laxity and mechanical instability.

Chronic varus positioning can progressively stretch these structures.

First Metatarsal Position

The relative position of the first metatarsal should be compared with the lesser metatarsals.

A plantarflexed first ray is characteristic of CMT-associated cavus.

Toe Clawing

The presence and severity of clawing should be documented.

The examiner should determine whether the toe deformities are flexible or fixed.

Gait Examination

Gait should be observed for foot drop, steppage, circumduction, ankle instability, and abnormal push-off.

Functional gait findings help determine the clinical severity of disease.

Hip Examination

Hip abduction should be measured.

Restricted abduction may suggest associated hip dysplasia and should prompt further imaging.

Spine Examination

The spine should be evaluated for scoliosis using a forward-bend test and observation of shoulder and trunk symmetry.

Upper-Extremity Examination

The hands should be inspected for wasting of the ulnar-innervated intrinsic muscles, including the interossei and abductors.

Upper-extremity weakness tends to develop later than lower-extremity involvement.

Electrodiagnostic Studies

Electromyography and nerve conduction studies are commonly used to confirm the diagnosis and characterize the neuropathy.

They help distinguish predominantly demyelinating disease from axonal forms.

Electromyography

EMG may demonstrate increased motor unit duration and reduced amplitude, reflecting chronic denervation and reinnervation.

Nerve Conduction Studies

Motor and sensory nerve conduction velocities are reduced to varying degrees.

Marked slowing is especially characteristic of demyelinating forms such as CMT Type I.

Hand Function Testing

Grip strength and manual dexterity may be monitored over time.

The 9-hole peg test can be used to quantify changes in fine motor function.

Biopsy

Muscle and nerve biopsy are rarely required when the history, examination, electrodiagnostic findings, and genetic testing are characteristic.

Muscle Biopsy Findings

Muscle biopsy may demonstrate diffuse atrophy with replacement of normal muscle fibers by fibrous and adipose tissue.

Nerve Biopsy Findings

Nerve biopsy may show loss of myelinated fibers and increased fibrous tissue within the endoneurium and perineurium.

Because genetic and electrodiagnostic testing are less invasive, biopsy is generally unnecessary.

Genetic Testing

DNA testing can be performed from peripheral blood.

It may confirm the diagnosis, identify a specific subtype, allow testing of family members, and assist with genetic counseling.

Imaging

Standing Foot and Ankle Radiographs

Weight-bearing radiographs should be obtained to evaluate cavus alignment, hindfoot varus, first-ray plantarflexion, joint congruity, and degenerative arthritis.

They are particularly important for surgical planning.

Spine Radiographs

In an index patient without a known family history, spinal radiographs may be obtained to exclude other structural causes of cavus deformity.

They are also appropriate when scoliosis is identified clinically.

Pelvic Radiographs

Pelvic radiographs should be considered when hip abduction is limited or dysplasia is suspected.

Early identification of hip dysplasia allows more effective treatment.

MRI of the Spine

Spinal MRI may be appropriate when the diagnosis is uncertain or there is concern for spinal pathology.

It can demonstrate abnormalities of the spinal cord and help exclude other neurologic causes of cavus deformity.

Differential Diagnosis

Important differential diagnoses include tethered spinal cord, myelomeningocele, lipomeningocele, peroneal nerve palsy, early Duchenne muscular dystrophy, and other hereditary motor and sensory neuropathies.

An atypical or unilateral deformity should prompt particularly careful investigation for a focal neurologic cause.

Treatment

General Principles

Treatment aims to maintain mobility, preserve flexibility, improve alignment, reduce pain, support weak muscles, and prevent progression of secondary deformity.

Orthopaedic treatment cannot reverse the underlying genetic neuropathy.

Routine Surveillance

Patients should be followed regularly for progression of muscle weakness, foot deformity, ankle instability, sensory loss, and functional limitation.

Earlier treatment may prevent a flexible deformity from becoming rigid.

Stretching

Regular stretching of the Achilles tendon and plantar fascia may help preserve foot and ankle flexibility.

Stretching is most useful before fixed contracture has developed.

Orthotic Insoles

Custom orthoses can redistribute plantar pressure and improve alignment.

A lateral heel build-up or wedge may help reduce flexible hindfoot varus.

Forefoot Padding

Accommodative padding beneath the forefoot may help relieve metatarsalgia and pressure associated with claw toes.

Ankle Bracing

An ankle brace may provide support in patients with symptomatic instability or recurrent ankle sprains.

Ankle-Foot Orthosis

A custom ankle-foot orthosis (AFO) may be necessary for substantial foot drop caused by dorsiflexor weakness.

It improves toe clearance during swing and may reduce falls.

Footwear

Comfortable footwear with a wide toe box, adequate depth, and cushioned heel is recommended.

Shoes should accommodate claw toes, high arches, and pressure-sensitive areas.

Physical Therapy

Physical therapy may include Achilles and plantar fascia stretching, strengthening exercises, gait work, proprioceptive training, and balance exercises.

These measures can improve function and reduce instability but do not reverse the neuropathy itself.

Surgery

General Surgical Principles

Surgical treatment should be individualized according to the flexibility and location of the deformity.

As a general principle, flexible deformities are managed with soft-tissue releases, rigid deformities require osteotomies, and tendon transfers are used to rebalance abnormal muscle forces.

The goal is to obtain a stable, plantigrade, pain-free, and braceable foot.

Claw-Toe Correction

Claw toes may be treated with flexor-to-extensor tendon transfer, MTP joint release, or PIP joint fusion, depending on whether the deformity remains flexible.

Jones Procedure

Severe hallux clawing may be treated with hallux interphalangeal arthrodesis combined with transfer of the extensor hallucis longus tendon to the first metatarsal.

This combination is commonly known as a Jones procedure.

Plantar Release

Soft-tissue release may involve the plantar fascia, abductor hallucis, and toe flexors.

This helps reduce the cavus deformity and increase flexibility.

Plantar-Medial Release

More extensive deformity may require a plantar-medial release involving structures such as the posterior tibialis, long toe flexors, and talonavicular capsule.

Posterior Tibialis Transfer

The posterior tibialis tendon may be transferred partially or completely toward the anterior aspect of the foot.

This can improve dorsiflexion and eversion while reducing the deforming inversion force.

Peroneus Longus to Brevis Transfer

Transfer or tenodesis of the peroneus longus to the peroneus brevis reduces plantarflexion of the first ray and increases eversion strength.

This is particularly useful in flexible forefoot-driven cavovarus deformity.

Calcaneal Osteotomy

A lateral closing-wedge calcaneal osteotomy may be required when hindfoot varus is rigid.

The procedure repositions the heel toward neutral alignment.

Midfoot and Metatarsal Osteotomies

Rigid cavus involving the forefoot or midfoot may require midfoot or metatarsal closing-wedge osteotomies.

These procedures reduce the high arch and improve plantar pressure distribution.

Triple Arthrodesis

Triple arthrodesis is generally reserved for severe rigid deformity or painful hindfoot arthritis.

Fusion sacrifices motion but can provide a stable and better-aligned foot.

Ankle Ligament Reconstruction

Chronic lateral ankle instability may require ligament reconstruction.

The underlying cavovarus deformity should also be corrected because isolated ligament repair may fail if varus alignment persists.

Follow-Up

Specialist Referral

Neurologic consultation is appropriate for electrodiagnostic evaluation, genetic testing, and counseling.

Management often benefits from collaboration among neurology, orthopaedics, physical therapy, orthotics, and genetics specialists.

Prognosis

Even after appropriate surgery, the foot generally cannot be restored completely to normal because the underlying muscle weakness continues.

Progressive neuropathy may lead to further weakness or recurrence of deformity.

Life Expectancy

Typical Charcot–Marie–Tooth disease does not shorten life expectancy.

Most morbidity relates to progressive weakness, deformity, gait difficulty, and loss of distal function.

Recurrence

Deformity can recur after surgery, especially when soft-tissue procedures alone are used in a foot that already has fixed bony malalignment.

Successful reconstruction requires correction of both structural deformity and muscle imbalance.

Adjacent-Joint Degeneration

Fusion procedures, particularly triple arthrodesis, may transfer mechanical stress to neighboring joints.

This can contribute to later degeneration of the ankle or midfoot.

Hip Dysplasia

Failure to recognize associated hip dysplasia may make later treatment more difficult and less successful.

Routine hip examination is therefore important throughout growth.

Patient Monitoring

Patients should generally be reviewed yearly for ambulatory function, muscle strength, foot alignment, ankle stability, sensory changes, hand function, and spinal deformity.

Earlier reassessment is appropriate if there is rapid deterioration, new weakness, recurrent falls, worsening pain, or progression of deformity.

Medicine – Iron Metabolism and Iron Studies

Iron is an essential trace element required for haemoglobin synthesis, oxygen transport, myoglobin function and numerous cellular enzymes. Because the body has no regulated pathway for active iron excretion, iron balance is controlled mainly by regulating intestinal absorption.

1. Total Body Iron

A normal adult contains approximately:

3–4 g of iron, though the exact amount varies with sex, body size and iron stores.

About:

Two-thirds of total body iron is present in haemoglobin.

The remainder is found mainly in:

Ferritin and haemosiderin stores.

Myoglobin.

Iron-containing enzymes.

2. Iron in Haemoglobin

Haemoglobin contains the largest functional pool of iron.

Iron is incorporated into:

Haem

within red blood cells.

Its major role is:

Reversible binding and transport of oxygen.

Therefore:

IRON DEFICIENCY → IMPAIRED HAEMOGLOBIN SYNTHESIS → MICROCYTIC HYPOCHROMIC ANAEMIA.

3. Dietary Iron Intake

The original notes state that a normal diet contains about:

20 mg iron/day

with about:

10% absorbed.

This is a reasonable traditional approximation.

In practice, daily dietary intake is often around:

10–20 mg/day,

while only approximately:

1–2 mg/day

needs to be absorbed to replace normal physiological losses.

4. Why Only a Small Amount Is Absorbed

The intestine tightly regulates iron uptake because excess iron cannot be readily excreted.

Therefore the body usually absorbs only a:

Small fraction of dietary iron.

Absorption increases when iron requirements rise, for example in:

Iron deficiency.

Pregnancy.

Increased erythropoiesis.

5. Site of Iron Absorption

Iron is absorbed mainly in the:

Duodenum and proximal jejunum.

The form of iron and the dietary environment strongly influence how efficiently it is absorbed.

6. Ferrous and Ferric Iron

The original notes correctly state:

Fe²⁺ is more readily absorbed than Fe³⁺.

Fe²⁺ = ferrous iron.

Fe³⁺ = ferric iron.

Non-haem ferric iron generally needs to be reduced to the ferrous form before efficient intestinal uptake.

Therefore:

Fe³⁺ → reduction → Fe²⁺ → intestinal absorption.

7. Role of Gastric Acid and Vitamin C

An acidic environment helps keep iron soluble and promotes conversion toward the more absorbable:

Ferrous Fe²⁺ form.

Vitamin C can also increase non-haem iron absorption by:

Reducing Fe³⁺ to Fe²⁺

and keeping iron soluble.

8. Factors That Reduce Iron Absorption

Iron absorption may be reduced by:

Phytates.

Some polyphenols, including those in tea and coffee.

Calcium in some contexts.

Reduced gastric acidity.

Inflammation through increased hepcidin.

Therefore the amount of dietary iron is not the same as the amount actually absorbed.

9. Hepcidin – Main Regulator of Iron Balance

The major hormonal regulator of systemic iron metabolism is:

Hepcidin.

Hepcidin is produced mainly by the:

Liver.

It controls iron entry into the circulation by regulating:

Ferroportin.

10. Ferroportin

Ferroportin exports iron from:

Enterocytes.

Macrophages.

Hepatocytes.

When hepcidin binds ferroportin, ferroportin is internalised and degraded.

Therefore:

↑ Hepcidin → ↓ iron absorption and ↓ iron release into plasma.

11. Hepcidin in Iron Deficiency

When iron stores are low:

Hepcidin decreases.

This allows greater ferroportin activity and therefore:

Increased intestinal iron absorption.

Increased release of stored iron.

12. Hepcidin in Inflammation

Inflammation, particularly through cytokines such as:

IL-6,

increases hepcidin production.

This traps iron inside macrophages and reduces intestinal iron absorption.

Therefore:

INFLAMMATION → ↑ HEPCIDIN → ↓ SERUM IRON DESPITE STORED IRON.

This is central to:

Anaemia of chronic inflammation.

13. Transferrin

Once iron enters the circulation, it binds mainly to:

Transferrin.

Transferrin is the principal plasma protein that:

Transports iron.

It carries iron to tissues, particularly the:

Bone marrow

for haemoglobin production.

14. Transferrin Saturation

The original notes state that transferrin is normally:

About one-third saturated.

This is a useful approximation.

Normal transferrin saturation is commonly around:

20–45%.

Therefore roughly one-quarter to one-third of available transferrin-binding sites are occupied by iron in many healthy adults.

15. Calculation of Transferrin Saturation

Transferrin saturation represents the proportion of transferrin iron-binding capacity occupied by iron.

Conceptually:

Transferrin saturation = serum iron / total iron-binding capacity × 100%.

It is especially useful when investigating:

Iron deficiency

and

Iron overload.

16. Transferrin Saturation in Iron Deficiency

In iron deficiency:

Serum iron falls.

Transferrin/TIBC often rises.

Therefore:

Transferrin saturation falls.

A low transferrin saturation supports:

Insufficient circulating iron available for erythropoiesis.

17. Transferrin Saturation in Iron Overload

In iron overload, more transferrin-binding sites become occupied.

Therefore:

Transferrin saturation rises.

Persistently high saturation is an important clue to:

Hereditary haemochromatosis

or other iron-loading states.

18. Ferritin

Ferritin is the major intracellular iron-storage protein.

Serum ferritin broadly reflects:

Body iron stores.

Therefore:

Low ferritin → strongly suggests iron deficiency.

High ferritin → may indicate iron overload.

However, interpretation is more complicated when inflammation is present.

19. Ferritin in Iron Deficiency

A reduced ferritin is one of the most useful findings in diagnosing:

Iron deficiency.

It indicates depletion of:

Stored iron.

Therefore:

LOW FERRITIN = IRON DEFICIENCY UNTIL PROVEN OTHERWISE, provided there is no unusual laboratory issue.

20. Ferritin in Iron Overload

Ferritin may rise when iron stores increase.

Examples include:

Hereditary haemochromatosis.

Repeated transfusions.

Other secondary iron-loading disorders.

However, ferritin alone cannot prove true iron overload.

21. Ferritin as an Acute-Phase Reactant

The original notes correctly state that ferritin is also raised in:

Acute and chronic inflammation.

Ferritin can increase with:

Infection.

Inflammatory disease.

Liver injury.

Malignancy.

Therefore:

HIGH FERRITIN ≠ AUTOMATICALLY HIGH IRON STORES.

22. Ferritin in Chronic Inflammation

A patient with inflammation may have:

Normal or high ferritin

despite having insufficient iron available for red-cell production.

This occurs because inflammation increases:

Hepcidin.

Iron becomes trapped within storage cells.

Therefore:

Ferritin may look adequate while serum iron and transferrin saturation are low.

23. Plasma or Serum Iron

The original notes correctly state:

Plasma iron varies.

Serum iron can fluctuate significantly during the day and is influenced by:

Recent dietary intake.

Inflammation.

Time of sampling.

Iron supplementation.

Therefore serum iron by itself is:

Not a reliable measure of total body iron stores.

24. Why Serum Iron Should Not Be Used Alone

A patient with iron deficiency may occasionally have a serum iron that is not profoundly reduced.

Conversely, a patient with inflammation may have low serum iron despite adequate or increased body iron stores.

Therefore iron status is better assessed using a combination of:

Ferritin.

Transferrin or TIBC.

Transferrin saturation.

Full blood count and red-cell indices.

25. Iron Deficiency – Typical Iron Study Pattern

A typical pattern is:

Ferritin ↓.

Serum iron ↓.

Transferrin/TIBC ↑.

Transferrin saturation ↓.

As deficiency progresses:

MCV ↓

and

MCH ↓.

This produces:

Microcytic hypochromic anaemia.

26. Iron Overload – Typical Pattern

Iron overload commonly produces:

Ferritin ↑.

Serum iron ↑.

Transferrin saturation ↑.

TIBC/transferrin may be normal or reduced depending on the underlying condition.

In hereditary haemochromatosis, a particularly useful early clue is:

Raised transferrin saturation.

27. Anaemia of Chronic Inflammation – Typical Pattern

Inflammation causes:

↑ Hepcidin.

Therefore iron becomes less available to the marrow.

Typical findings include:

Serum iron ↓.

Transferrin/TIBC ↓ or normal.

Transferrin saturation ↓.

Ferritin normal or ↑.

This differs importantly from uncomplicated iron deficiency.

28. Iron Recycling

Most iron used each day for new red-cell production does not come directly from the diet.

Instead, it comes from:

Recycling of old red blood cells.

Macrophages break down senescent erythrocytes and recover iron from:

Haemoglobin.

That iron is returned to plasma through:

Ferroportin

and carried by:

Transferrin.

29. Daily Iron Turnover

The bone marrow requires a much larger amount of iron each day for erythropoiesis than is absorbed from the gut.

Most of this requirement is supplied by:

Macrophage recycling.

Only the small amount lost from the body needs to be replaced by:

Intestinal absorption.

30. Body Iron – Note Form

Total body iron:

Approximately 3–4 g in a typical adult.

About two-thirds:

Contained within haemoglobin.

Remaining iron:

Ferritin/haemosiderin stores.

Myoglobin.

Enzymes.

31. Dietary Iron – Note Form

Dietary intake:

Approximately 10–20 mg/day in many diets.

↓

Only a small fraction absorbed.

↓

Approximately 1–2 mg/day normally enters the body.

Main absorption site:

Duodenum/proximal jejunum.

32. Ferrous Versus Ferric Iron – Note Form

Fe²⁺ = ferrous iron.

More readily absorbed.

Fe³⁺ = ferric iron.

Usually must be reduced before efficient absorption.

Therefore:

Fe³⁺ → Fe²⁺ → intestinal uptake.

33. Transferrin – Note Form

Function:

Transports iron in plasma.

Normal saturation:

Approximately 20–45%, traditionally described as about one-third saturated.

Iron deficiency:

Transferrin saturation ↓.

Iron overload:

Transferrin saturation ↑.

34. Ferritin – Note Form

Ferritin = storage protein.

Iron deficiency:

Ferritin ↓.

Iron overload:

Ferritin often ↑.

Inflammation/infection/liver disease:

Ferritin may also ↑.

Therefore:

Ferritin must be interpreted in clinical context.

35. Serum Iron – Note Form

Serum iron varies considerably.

Therefore it should:

Not be interpreted alone.

Use it with:

Ferritin + transferrin/TIBC + transferrin saturation.

36. Important Clarifications to the Original Notes

The statement:

“4 g in the normal human body”

is a reasonable traditional approximation, but total body iron varies. A practical modern figure is:

Approximately 3–4 g in a typical adult.

The statement:

“20 mg/day in normal diet; only 10% absorbed”

is also a useful approximation.

The more physiologically important point is that only around:

1–2 mg/day normally needs to be absorbed

because most iron is continuously recycled from old red cells.

The statement:

“Fe²⁺ more readily absorbed than Fe³⁺”

is correct.

The statement:

“Transferrin one-third saturated normally”

is a useful approximation; typical laboratory ranges are around:

20–45%.

The statement:

“Ferritin increased in iron overload, decreased in deficiency”

is correct, but remember:

Ferritin is an acute-phase reactant.

Therefore inflammation can produce:

High ferritin even when circulating available iron is low.

Key Clinical Pattern

For rapid recall:

HAEMOGLOBIN = MAIN BODY IRON POOL.

TRANSFERRIN = IRON TRANSPORT.

FERRITIN = IRON STORAGE.

HEPCIDIN = MASTER REGULATOR OF IRON ENTRY INTO PLASMA.

Fe²⁺ IS ABSORBED MORE EASILY THAN Fe³⁺.

For iron studies:

IRON DEFICIENCY → ↓ ferritin + ↓ serum iron + ↑ TIBC/transferrin + ↓ transferrin saturation.

IRON OVERLOAD → ↑ ferritin + ↑ transferrin saturation.

CHRONIC INFLAMMATION → ↓ serum iron + ↓/normal transferrin + normal/↑ ferritin.

Medicine – Haemochromatosis

Haemochromatosis is a disorder of excessive body iron accumulation caused by increased intestinal iron absorption. Over time, excess iron is deposited in organs such as the liver, pancreas, heart, joints, skin and endocrine glands, where it can produce progressive tissue injury.

The classic inherited form is:

Hereditary haemochromatosis.

1. Inheritance

The common HFE-associated form of hereditary haemochromatosis is inherited in an:

Autosomal recessive – AR pattern.

This means clinically important disease generally develops when a person inherits pathogenic variants affecting both copies of the relevant gene.

2. HFE Gene

The common form is associated with abnormalities in the:

HFE gene

located on:

Chromosome 6.

The most important variant is:

C282Y.

Another common variant is:

H63D.

3. Important Genetic Clarification

The original notes list:

C282Y and H63D mutations.

This is broadly correct, but the strongest association with classical clinically significant HFE haemochromatosis is:

C282Y homozygosity.

H63D alone usually has much lower penetrance and is much less likely to cause severe iron overload.

Some individuals are:

C282Y/H63D compound heterozygotes,

but clinically significant iron overload is still much less predictable than in C282Y homozygotes.

4. Basic Pathophysiology

The central abnormality is inappropriate increase in:

Intestinal iron absorption.

Normally iron absorption is tightly controlled because the body has no effective physiological mechanism for excreting large amounts of excess iron.

5. Role of Hepcidin

A key regulator is:

Hepcidin.

Hepcidin is produced mainly by the:

Liver.

It reduces iron entry into the circulation by causing internalisation and degradation of:

Ferroportin.

6. Ferroportin

Ferroportin is an iron export protein found on cells such as:

Enterocytes.

Macrophages.

When hepcidin activity is inadequate:

Ferroportin remains active.

Therefore more iron enters the bloodstream.

7. Mechanism in HFE Haemochromatosis

The simplified pathway is:

HFE abnormality

↓

Inappropriately low hepcidin activity

↓

Increased ferroportin activity

↓

Increased intestinal iron absorption

↓

Progressive iron accumulation

↓

Organ damage.

8. Why Men Are More Commonly and Severely Affected

The original notes correctly state that haemochromatosis is:

More commonly clinically apparent and often more severe in men.

Premenopausal women lose iron through:

Menstruation

and

Pregnancy.

This delays iron accumulation.

Therefore women may present later, often after:

Menopause.

9. Clinical Penetrance

An important modern point is that not every person with a susceptible HFE genotype develops severe clinical disease.

This is called:

Incomplete penetrance.

Disease severity depends on factors such as:

Sex.

Age.

Alcohol intake.

Other liver disease.

Metabolic risk factors.

10. Liver Disease

The liver is one of the major organs affected by iron deposition.

Progressive iron accumulation can cause:

Hepatomegaly.

Fibrosis.

Cirrhosis.

Therefore the original association with:

Liver cirrhosis

is correct.

11. Hepatocellular Carcinoma

Patients who develop haemochromatosis-related cirrhosis have an increased risk of:

Hepatocellular carcinoma – HCC.

This risk is particularly associated with established:

Cirrhosis or advanced fibrosis.

Therefore preventing advanced hepatic iron injury is an important objective of early diagnosis and treatment.

12. Skin Bronzing

The original notes correctly include:

Skin bronzing.

Skin pigmentation results from a combination of:

Increased melanin

and

Iron deposition.

The skin may develop a:

Bronze or slate-grey appearance.

13. Diabetes Mellitus

Iron can accumulate in the:

Pancreas.

Damage to pancreatic beta cells and associated metabolic disturbances can lead to:

Diabetes mellitus.

The traditional combination of:

Bronze skin + diabetes

gave rise to the historical term:

“Bronze diabetes.”

14. Arthropathy

Joint disease is an important manifestation of haemochromatosis.

Patients may develop:

Chronic arthropathy.

Classically affected joints include the:

Second and third metacarpophalangeal joints.

15. Chondrocalcinosis

The original notes correctly include:

Chondrocalcinosis.

Haemochromatosis is associated with deposition of:

Calcium pyrophosphate crystals.

This can produce:

CPPD disease

and may resemble:

Pseudogout.

Therefore:

HAEMOCHROMATOSIS + MCP ARTHROPATHY + CHONDROCALCINOSIS

is a useful examination association.

16. Cardiomyopathy

Iron deposition in cardiac tissue can cause:

Cardiomyopathy.

The heart may develop:

Systolic dysfunction.

Diastolic dysfunction.

Arrhythmias.

Advanced disease can result in:

Heart failure.

17. Endocrine Manifestations

Iron can also accumulate in endocrine organs.

Possible consequences include:

Hypogonadism.

Loss of libido.

Erectile dysfunction.

Infertility.

Other endocrine abnormalities may occur in severe iron overload.

18. Typical Clinical Features – Note Form

Liver:

Hepatomegaly.

Fibrosis.

Cirrhosis.

Increased HCC risk when cirrhosis is present.

Skin:

Bronze or slate-grey pigmentation.

Pancreas:

Diabetes mellitus.

Joints:

MCP arthropathy.

Chondrocalcinosis.

CPPD/pseudogout.

Heart:

Cardiomyopathy.

Arrhythmias.

Heart failure.

Endocrine system:

Hypogonadism.

Reduced libido.

Sexual dysfunction.

19. Diagnosis

The original notes include:

Raised serum iron and ferritin.

Increased transferrin saturation.

HFE genetic testing.

Liver biopsy.

These remain relevant, but the modern diagnostic approach places particular emphasis on:

Transferrin saturation and ferritin, followed by appropriate genetic testing.

20. Transferrin Saturation

Transferrin saturation – TSAT measures the proportion of transferrin binding sites occupied by iron.

It is calculated from measures of circulating iron and transferrin or total iron-binding capacity.

In hereditary haemochromatosis, TSAT is often:

Elevated early.

A persistent TSAT around:

≥45%

commonly raises suspicion for iron overload, although thresholds and interpretation depend on the clinical context and laboratory.

21. Serum Ferritin

Ferritin reflects:

Stored iron.

Ferritin may rise progressively as iron stores increase.

However, ferritin is also an:

Acute-phase reactant.

Therefore it can be elevated by:

Inflammation.

Infection.

Alcohol-related liver disease.

Metabolic liver disease.

Other liver injury.

So:

HIGH FERRITIN ≠ AUTOMATICALLY HAEMOCHROMATOSIS.

22. Serum Iron

Serum iron may be elevated, but it fluctuates and is not usually interpreted alone.

More informative measurements include:

Transferrin saturation

and

Ferritin.

23. Genetic Testing

If biochemical iron studies suggest hereditary haemochromatosis, genetic testing may identify:

HFE variants.

Particular attention is given to:

C282Y.

Testing can help distinguish inherited HFE haemochromatosis from secondary iron overload.

24. C282Y Homozygosity

The classic genotype is:

C282Y/C282Y.

However, genotype alone does not necessarily mean severe clinical disease.

The degree of actual iron loading should still be assessed with:

Ferritin.

Transferrin saturation.

Evidence of organ involvement.

25. Role of Liver MRI

A major modern addition is:

MRI assessment of liver iron.

MRI can estimate hepatic iron concentration non-invasively and may help determine:

The extent of iron overload

and

Whether tissue deposition is significant.

26. Liver Biopsy

The original notes include:

Liver biopsy.

Historically, biopsy was commonly used to confirm hepatic iron deposition and assess fibrosis.

Today, biopsy is:

Not routinely required for every patient.

It is more likely to be considered when:

The diagnosis is uncertain.

Advanced fibrosis/cirrhosis needs clarification.

Another liver disease is suspected.

27. Histology

When biopsy is performed, iron can be demonstrated using:

Perls’ Prussian blue stain.

In hereditary haemochromatosis, iron classically accumulates initially in:

Hepatocytes.

With increasing severity, deposition becomes more widespread.

28. Treatment

The central treatment for hereditary haemochromatosis is:

Therapeutic venesection – phlebotomy.

This is the treatment of choice for most suitable patients with significant iron overload.

29. Mechanism of Venesection

Removal of blood removes:

Red blood cells containing haemoglobin-bound iron.

The body then uses stored iron to produce replacement red cells.

Repeated venesection therefore gradually reduces:

Total body iron stores.

30. Initial Venesection Phase

During the iron-depletion phase, blood is removed repeatedly according to:

Haemoglobin.

Ferritin.

Clinical tolerance.

The aim is to bring iron stores into an appropriate low-normal target range without causing:

Anaemia.

31. Maintenance Treatment

After excess iron has been removed, patients may require:

Maintenance venesection

at intervals to prevent reaccumulation.

The frequency varies substantially between individuals.

32. Desferrioxamine

The original notes include:

Desferrioxamine, also spelled:

Deferoxamine.

This is an:

Iron-chelating drug.

It binds iron and facilitates its elimination.

33. Is Deferoxamine Routine Treatment for Hereditary Haemochromatosis?

This requires an important correction.

For typical hereditary haemochromatosis, the preferred treatment is:

VENesection / phlebotomy.

Iron chelation is generally reserved for patients in whom venesection is:

Contraindicated, poorly tolerated, or impossible.

For example, venesection may be difficult in patients with significant:

Anaemia.

34. Other Iron Chelators

Other chelating agents include:

Deferasirox.

Deferiprone.

These are used more commonly in certain forms of:

Secondary/transfusional iron overload

than in routine HFE haemochromatosis.

35. Venesection Versus Chelation – Note Form

Hereditary haemochromatosis:

Excess iron but generally adequate red-cell production.

↓

Blood can be removed.

↓

VENesection is preferred.

Transfusional iron overload with chronic anaemia:

Removing blood may worsen anaemia.

↓

IRON CHELATION is often preferred.

This distinction is very important.

36. Effects of Treatment

Venesection can improve or prevent progression of several manifestations, particularly if started before irreversible organ damage develops.

It may improve:

Fatigue.

Liver abnormalities.

Skin pigmentation.

Some metabolic abnormalities.

37. Less Reversible Manifestations

Some complications may not completely reverse even after iron removal.

These include established:

Cirrhosis.

Arthropathy.

Advanced cardiomyopathy.

Long-standing endocrine damage.

This is why early diagnosis matters.

38. Alcohol and Haemochromatosis

Excess alcohol intake can substantially worsen liver injury in a person with iron overload.

Therefore alcohol exposure can accelerate progression toward:

Fibrosis and cirrhosis.

Patients with hepatic iron overload should be assessed for coexisting liver risk factors.

39. Haemochromatosis – Note Form

Inheritance:

Autosomal recessive.

Gene:

HFE gene.

Chromosome 6.

Most important classic variant:

C282Y.

H63D is less strongly associated with severe disease.

Mechanism:

↓ effective hepcidin signalling.

↓

↑ ferroportin activity.

↓

↑ intestinal iron absorption.

↓

Progressive tissue iron deposition.

Men:

Usually earlier and more severe clinical expression.

Women:

Menstruation/pregnancy delay iron accumulation.

Often later presentation.

40. Clinical Features – Note Form

Cirrhosis.

Skin bronzing.

Diabetes mellitus.

Cardiomyopathy.

Chondrocalcinosis/CPPD arthropathy.

MCP joint disease.

Hypogonadism.

41. Diagnosis – Note Form

Transferrin saturation ↑

often an early biochemical clue.

Ferritin ↑

suggests increased iron stores but is nonspecific.

HFE gene testing

particularly C282Y.

MRI liver iron

useful non-invasive assessment.

Liver biopsy

selected cases rather than routine diagnosis for everyone.

42. Treatment – Note Form

First-line:

Therapeutic venesection.

↓

Removes haemoglobin-bound iron.

↓

Stored iron used to make new RBCs.

↓

Total body iron falls.

Chelation:

Deferoxamine/desferrioxamine or other chelators.

Used mainly when:

Venesection cannot be performed.

43. Important Corrections to the Original Notes

The statement:

“AR”

is correct for classical HFE-associated hereditary haemochromatosis.

The statement:

“More common and more severe in men”

is broadly correct clinically, largely because women lose iron physiologically through menstruation and pregnancy.

The diagnosis is better described as:

↑ TRANSFERRIN SATURATION + ↑ FERRITIN → consider HFE genetic testing.

Serum iron alone is:

Not sufficient for diagnosis.

The major genetic association is:

C282Y homozygosity.

H63D is a recognised HFE variant but usually has:

Much lower clinical penetrance.

Liver biopsy is no longer routinely necessary in every patient.

MRI and non-invasive fibrosis assessment have reduced the need for biopsy.

The treatment statement should be refined from:

“Venesection, desferrioxamine”

to:

VENESECTION IS THE STANDARD FIRST-LINE TREATMENT FOR MOST HEREDITARY HAEMOCHROMATOSIS.

IRON CHELATION IS RESERVED FOR SELECTED PATIENTS WHO CANNOT UNDERGO VENESECTION.

Key Clinical Pattern

For rapid recall:

HAEMOCHROMATOSIS → AR HFE DISORDER → ↓ HEPCIDIN EFFECT → ↑ INTESTINAL IRON ABSORPTION.

Think of:

LIVER → CIRRHOSIS.

SKIN → BRONZING.

PANCREAS → DIABETES.

HEART → CARDIOMYOPATHY.

JOINTS → MCP ARTHROPATHY + CHONDROCALCINOSIS.

ENDOCRINE → HYPOGONADISM.

For diagnosis:

↑ TRANSFERRIN SATURATION + ↑ FERRITIN → HFE TESTING.

For treatment:

HEREDITARY HAEMOCHROMATOSIS → VENESECTION.

SECONDARY TRANSFUSIONAL IRON OVERLOAD → OFTEN IRON CHELATION.

Medicine – Causes of Secondary Iron Overload

Secondary iron overload occurs when excess iron accumulates because of another disease, repeated iron exposure, or chronic liver pathology rather than because of a primary inherited defect in iron regulation.

The important causes in your notes are:

Multiple transfusions.

Alcohol-related cirrhosis.

Chronic hepatitis B or C.

1. Multiple Blood Transfusions

Repeated transfusion is one of the most important causes of secondary iron overload.

Each unit of packed red blood cells contains a substantial amount of:

Iron.

The human body has no regulated mechanism for actively excreting large amounts of excess iron.

Therefore:

Repeated transfusions → progressive iron accumulation → tissue deposition.

2. Conditions Requiring Repeated Transfusions

Transfusional iron overload may occur in patients with chronic anaemias such as:

Thalassaemia major.

Myelodysplastic syndromes.

Sickle cell disease in heavily transfused patients.

Severe chronic bone-marrow failure disorders.

Over time, iron may accumulate in the:

Liver.

Heart.

Endocrine organs.

3. Complications of Transfusional Iron Overload

Excess iron can cause oxidative tissue damage.

Important complications include:

Hepatic fibrosis and cirrhosis.

Cardiomyopathy and arrhythmias.

Diabetes mellitus.

Hypogonadism and other endocrine dysfunction.

Therefore long-term transfusion programmes require monitoring for iron loading.

4. Alcohol-Related Cirrhosis

The original notes correctly include:

Alcoholic cirrhosis, more commonly termed alcohol-related cirrhosis or alcohol-associated liver disease.

Chronic alcohol exposure can disturb iron metabolism and increase hepatic iron accumulation.

5. Mechanism in Alcohol-Related Liver Disease

Alcohol can increase intestinal iron absorption and alter hepatic regulation of:

Hepcidin.

Reduced effective hepcidin activity promotes greater release and absorption of iron.

At the same time, damaged hepatocytes may store excess iron.

Therefore:

Chronic alcohol-related liver disease → increased iron loading of the liver.

6. Alcohol and Ferritin

Alcohol-related liver disease may also cause:

Raised serum ferritin.

However, ferritin is an:

Acute-phase reactant.

Therefore a raised ferritin does not always mean true iron overload.

It may also reflect:

Inflammation.

Hepatocellular injury.

Alcohol use itself.

This is why iron studies need to be interpreted together.

7. Chronic Hepatitis B and C

The original notes also include:

Chronic hepatitis B and chronic hepatitis C.

Chronic viral hepatitis can be associated with abnormalities of iron handling and hepatic iron deposition.

The association is particularly recognised with:

Chronic hepatitis C.

8. Mechanism in Chronic Viral Hepatitis

Chronic liver inflammation can alter:

Hepcidin regulation.

This may increase iron absorption and promote deposition in the liver.

Hepatocyte injury can also release ferritin and complicate interpretation of iron studies.

Therefore patients may show:

Raised ferritin

and sometimes:

Raised transferrin saturation.

9. Hepatitis C and Iron Overload

In chronic hepatitis C, hepatic iron accumulation has been associated with more severe liver injury in some patients.

However, not every patient with hepatitis C develops clinically significant iron overload.

The important point is:

CHRONIC HCV CAN BE ASSOCIATED WITH SECONDARY HEPATIC IRON ACCUMULATION.

10. Other Important Causes of Secondary Iron Overload

Important additional causes include:

Ineffective erythropoiesis, especially in thalassaemia.

Excessive iron therapy.

Certain chronic anaemias.

Chronic liver disease from other causes.

These may increase iron absorption or add repeated external iron exposure.

11. Ineffective Erythropoiesis

In disorders such as:

Thalassaemia,

ineffective erythropoiesis suppresses hepcidin.

This causes increased intestinal iron absorption even without transfusion.

Therefore thalassaemia can cause iron overload through:

Two mechanisms.

12. Two Mechanisms in Thalassaemia

First:

Repeated transfusions → direct iron loading.

Second:

Ineffective erythropoiesis → ↓ hepcidin → ↑ intestinal iron absorption.

This explains why severe iron overload can occur particularly quickly in transfusion-dependent thalassaemia.

13. Diagnosis of Iron Overload

Evaluation commonly includes:

Serum ferritin.

Transferrin saturation.

Liver function tests.

In selected patients, tissue iron can be assessed more accurately using:

MRI-based liver iron measurement.

Cardiac MRI may also be used in heavily transfused patients to assess myocardial iron.

14. Ferritin and Transferrin Saturation

Ferritin reflects body iron stores but is affected by:

Inflammation.

Infection.

Liver disease.

Therefore ferritin alone is not enough.

Transferrin saturation helps estimate how much circulating transferrin is loaded with iron.

Marked persistent elevation can support:

Iron overload.

15. Treatment Principles

Treatment depends on the cause and severity.

In transfusional overload, treatment may include:

Iron chelation therapy.

Examples include agents such as:

Deferasirox.

Deferoxamine.

Deferiprone.

Choice depends on the clinical setting.

16. Venesection

Therapeutic phlebotomy is a major treatment for primary haemochromatosis.

However, in patients with secondary iron overload due to chronic anaemia or transfusion dependence, phlebotomy may not be feasible because removing blood would worsen:

Anaemia.

Therefore these patients often require:

Chelation rather than venesection.

17. Multiple Transfusions – Note Form

Repeated transfusions:

Each unit contains iron.

↓

Body cannot actively excrete excess iron.

↓

Progressive iron accumulation.

↓

Liver + heart + endocrine deposition.

↓

Secondary iron overload.

18. Alcohol-Related Cirrhosis – Note Form

Chronic alcohol exposure:

Altered hepcidin regulation.

↓

↑ intestinal iron absorption.

↓

Hepatic iron deposition.

↓

Secondary iron overload may develop.

19. Chronic Hepatitis B/C – Note Form

Chronic hepatic inflammation:

Altered iron regulation.

↓

Possible ↑ iron absorption and hepatic deposition.

↓

Raised ferritin ± raised transferrin saturation.

↓

Secondary hepatic iron overload.

20. Important Clarifications

The strongest classic cause in the original list is:

MULTIPLE TRANSFUSIONS.

This causes direct accumulation of exogenous iron.

Alcohol-related cirrhosis and chronic viral hepatitis can be associated with hepatic iron accumulation, but raised ferritin in liver disease does not automatically prove true iron overload.

Ferritin may rise simply because it is:

An acute-phase reactant and marker of hepatocellular injury.

In thalassaemia, remember that iron overload can occur from both:

TRANSFUSIONS

and

INCREASED GASTROINTESTINAL IRON ABSORPTION due to ineffective erythropoiesis.

Key Clinical Pattern

For rapid recall:

MULTIPLE TRANSFUSIONS → DIRECT IRON LOADING.

THALASSAEMIA → TRANSFUSIONS + ↓ HEPCIDIN/↑ IRON ABSORPTION.

ALCOHOL-RELATED CIRRHOSIS → ALTERED HEPCIDIN + HEPATIC IRON ACCUMULATION.

CHRONIC HEPATITIS B/C → CHRONIC LIVER INJURY + POSSIBLE SECONDARY IRON ACCUMULATION.

The key distinction is:

PRIMARY IRON OVERLOAD → inherited dysregulation of iron absorption.

SECONDARY IRON OVERLOAD → iron accumulation because of transfusion, ineffective erythropoiesis, liver disease, or excess iron exposure.

Medicine – Acid–Base Homeostasis and the Anion Gap

Acid–base homeostasis refers to the mechanisms that keep blood pH within a narrow physiological range despite continuous production of acids by normal metabolism. The major systems involved are chemical buffers, the lungs, and the kidneys.

A central buffer system in extracellular fluid is the:

Bicarbonate–carbon dioxide buffer system.

1. Bicarbonate Buffer Equation

The original reaction is:

H⁺ + HCO₃⁻ ↔ H₂O + CO₂.

This is a simplified way of showing how hydrogen ions are buffered by bicarbonate.

More completely:

H⁺ + HCO₃⁻ ↔ H₂CO₃ ↔ H₂O + CO₂.

Here:

H⁺ = hydrogen ion.

HCO₃⁻ = bicarbonate.

H₂CO₃ = carbonic acid.

CO₂ = carbon dioxide.

2. How the Buffer System Works

If excess acid is added to the blood:

H⁺ combines with HCO₃⁻.

This forms:

Carbonic acid.

Carbonic acid then becomes:

Water + carbon dioxide.

The CO₂ can be eliminated through the:

Lungs.

Therefore:

EXCESS H⁺ → CONSUMES HCO₃⁻ → PRODUCES CO₂ → CO₂ EXHALED.

3. Role of the Lungs

The lungs regulate the:

CO₂ component

of the bicarbonate buffer system.

If ventilation increases:

More CO₂ is exhaled.

Therefore:

PaCO₂ falls

and pH tends to:

Rise.

If ventilation decreases:

CO₂ is retained.

Therefore:

PaCO₂ rises

and pH tends to:

Fall.

This is why respiratory disorders alter acid–base balance so rapidly.

4. Role of the Kidneys

The kidneys regulate acid–base balance more slowly but very powerfully.

They help by:

Reabsorbing filtered bicarbonate.

Generating new bicarbonate.

Excreting hydrogen ions.

Excreting acid as ammonium and titratable acid.

Therefore the kidneys mainly control the:

HCO₃⁻ component

of the system.

5. Relationship Between pH, Bicarbonate and CO₂

Blood pH depends largely on the ratio between:

Bicarbonate

and

Dissolved CO₂.

The practical principle is:

pH ∝ HCO₃⁻ / PaCO₂.

Therefore:

↑ HCO₃⁻ → pH tends ↑.

↓ HCO₃⁻ → pH tends ↓.

↑ PaCO₂ → pH tends ↓.

↓ PaCO₂ → pH tends ↑.

6. Metabolic Versus Respiratory Disturbance

A primary abnormality in:

HCO₃⁻

produces a:

Metabolic acid–base disorder.

A primary abnormality in:

PaCO₂

produces a:

Respiratory acid–base disorder.

This gives the four major disorders:

Metabolic acidosis.

Metabolic alkalosis.

Respiratory acidosis.

Respiratory alkalosis.

7. Anion Gap

The anion gap – AG estimates the concentration of unmeasured negatively charged ions in plasma.

The original formula includes potassium:

Anion gap = ([Na⁺] + [K⁺]) − ([Cl⁻] + [HCO₃⁻]).

Using this formula, a traditional normal range is approximately:

10–18 mmol/L.

This matches the range in the original notes.

8. Why an Anion Gap Exists

Plasma must always remain electrically neutral.

Therefore:

Total positive charges = total negative charges.

However, routine blood chemistry measures only some ions.

Common measured cations include:

Na⁺

and sometimes:

K⁺.

Measured anions include:

Cl⁻

and

HCO₃⁻.

9. Unmeasured Anions

Several important negatively charged substances are not included directly in the standard calculation.

These include:

Albumin.

Phosphate.

Sulphate.

Lactate.

Ketone bodies.

Other organic acids.

The difference between measured cations and measured anions is called the:

Anion gap.

10. Modern Formula Without Potassium

In modern clinical practice, potassium is often omitted because its plasma concentration is small compared with sodium.

The commonly used formula is:

AG = Na⁺ − (Cl⁻ + HCO₃⁻).

With this formula, the traditional normal range is approximately:

8–12 mmol/L, although laboratory ranges vary.

Therefore it is important to know:

Whether potassium has been included in the calculation.

11. Why the Normal Range Changes

If potassium is included:

AG ≈ 10–18 mmol/L.

If potassium is omitted:

AG ≈ 8–12 mmol/L.

These ranges are approximate and depend on the:

Laboratory method and reference interval.

12. Clinical Importance of the Anion Gap

The anion gap is particularly useful when investigating:

Metabolic acidosis.

It helps divide metabolic acidosis into:

Normal anion gap metabolic acidosis

and

High anion gap metabolic acidosis.

13. Normal Anion Gap Metabolic Acidosis

In normal anion gap metabolic acidosis, bicarbonate is lost and is largely replaced by:

Chloride.

Therefore:

↓ HCO₃⁻ + ↑ Cl⁻

with no major accumulation of unmeasured anions.

This is also called:

Hyperchloraemic metabolic acidosis.

14. Causes of Normal Anion Gap Acidosis

Important causes include:

Diarrhoea.

Renal tubular acidosis.

Acetazolamide.

Type 4 RTA due to hypoaldosteronism, including Addison’s disease.

The general mechanism is:

Bicarbonate loss or impaired renal acid excretion.

15. High Anion Gap Metabolic Acidosis

In high anion gap metabolic acidosis, additional acids accumulate.

Their hydrogen ions consume bicarbonate, while their negatively charged conjugate bases remain in the circulation as:

Unmeasured anions.

Therefore:

↓ HCO₃⁻ + ↑ unmeasured anions → ↑ anion gap.

16. Causes of High Anion Gap Acidosis

Important causes include:

Diabetic ketoacidosis.

Lactic acidosis.

Advanced kidney failure.

Salicylate poisoning.

Methanol poisoning.

Ethylene glycol poisoning.

17. Example – Diabetic Ketoacidosis

In DKA:

Ketone acids accumulate.

Hydrogen ions are buffered by bicarbonate.

Therefore:

HCO₃⁻ falls.

The ketone anions remain in plasma.

Therefore:

Anion gap rises.

So:

DKA → ↓ HCO₃⁻ + ↑ ketone anions → HIGH ANION GAP.

18. Example – Diarrhoea

In diarrhoea:

Bicarbonate is directly lost from the gastrointestinal tract.

To maintain electrical neutrality, chloride rises.

Therefore:

↓ HCO₃⁻ + ↑ Cl⁻ → normal anion gap.

This explains why diarrhoeal acidosis is called:

Hyperchloraemic metabolic acidosis.

19. Albumin and the Anion Gap

A very important modern point is that:

Albumin is the major unmeasured plasma anion.

Therefore a patient with:

Hypoalbuminaemia

may have a deceptively low or apparently normal anion gap even when abnormal acids are accumulating.

20. Corrected Anion Gap

A commonly used approximate correction is:

For every 1 g/dL fall in albumin below 4 g/dL, add about 2.5 mmol/L to the measured anion gap.

Therefore severe hypoalbuminaemia can:

Mask a high anion gap metabolic acidosis.

This is particularly relevant in critically ill patients.

21. Bicarbonate Buffer – Note Form

H⁺ + HCO₃⁻

↓

H₂CO₃

↓

H₂O + CO₂

↓

CO₂ eliminated through lungs.

Therefore:

BICARBONATE BUFFERS H⁺.

LUNGS REMOVE CO₂.

KIDNEYS CONTROL HCO₃⁻ AND H⁺.

22. Anion Gap With Potassium – Note Form

AG = (Na⁺ + K⁺) − (Cl⁻ + HCO₃⁻).

Traditional normal range:

Approximately 10–18 mmol/L.

This corresponds to the formula in the original notes.

23. Anion Gap Without Potassium – Note Form

More commonly used clinically:

AG = Na⁺ − (Cl⁻ + HCO₃⁻).

Typical reference range:

Approximately 8–12 mmol/L.

Always interpret according to the local laboratory.

24. Normal Gap Acidosis – Note Form

HCO₃⁻ lost.

↓

Chloride rises.

↓

No major increase in unmeasured anions.

↓

NORMAL ANION GAP.

Examples:

Diarrhoea.

RTA.

Acetazolamide.

Hypoaldosteronism/type 4 RTA.

25. High Gap Acidosis – Note Form

Extra acid accumulates.

↓

H⁺ consumes HCO₃⁻.

↓

Acid anion remains unmeasured.

↓

ANION GAP INCREASES.

Examples:

DKA.

Lactic acidosis.

Renal failure.

Salicylates.

Methanol.

Ethylene glycol.

26. Important Clarifications

The original equation:

H⁺ + HCO₃⁻ ↔ H₂O + CO₂

is correct as a simplified representation of the bicarbonate buffer system.

The intermediate:

H₂CO₃

is often included when showing the full chemical reaction.

The original anion gap formula:

([Na⁺] + [K⁺]) − ([Cl⁻] + [HCO₃⁻])

is also valid.

However, modern clinical practice often omits:

K⁺.

Therefore the normal range depends on which formula is being used.

Key Clinical Pattern

Remember:

H⁺ + HCO₃⁻ ↔ H₂CO₃ ↔ H₂O + CO₂.

LUNGS regulate CO₂.

KIDNEYS regulate H⁺ and HCO₃⁻.

For the anion gap:

WITH K⁺ → approximately 10–18 mmol/L.

WITHOUT K⁺ → approximately 8–12 mmol/L.

And clinically:

NORMAL GAP ACIDOSIS → think bicarbonate loss or impaired renal acid excretion.

HIGH GAP ACIDOSIS → think accumulation of unmeasured acids.

Medicine – Acid–Base Disorders: pH, PaCO₂ and Bicarbonate Changes

The image summarises the characteristic changes in pH, PaCO₂ and bicarbonate (HCO₃⁻) in the four major acid–base disorders. The key to understanding the pattern is to identify which variable changes primarily and which variable changes as compensation.

1. Basic Principle

There are two major components controlling blood pH:

Respiratory component → PaCO₂

and

Metabolic component → HCO₃⁻.

A useful relationship is:

pH ∝ HCO₃⁻ / PaCO₂.

Therefore:

↑ HCO₃⁻ → pushes pH upward.

↓ HCO₃⁻ → pushes pH downward.

↑ PaCO₂ → pushes pH downward.

↓ PaCO₂ → pushes pH upward.

2. Metabolic Acidosis

The primary abnormality is:

↓↓ HCO₃⁻.

Loss of bicarbonate or accumulation of acid lowers the:

pH.

Therefore initially:

↓ HCO₃⁻ → ↓ pH.

3. Compensation in Metabolic Acidosis

The respiratory system compensates by:

Hyperventilation.

More CO₂ is exhaled, causing:

↓ PaCO₂.

Therefore the complete pattern is:

pH → ↓ or near normal if compensated.

PaCO₂ → ↓.

HCO₃⁻ → ↓↓.

The double arrow on bicarbonate indicates that this is the:

Primary disturbance.

4. Kussmaul Respiration

Severe metabolic acidosis may produce deep, rapid breathing called:

Kussmaul respiration.

This is particularly characteristic of:

Diabetic ketoacidosis.

The sequence is:

↓ HCO₃⁻ → acidosis → respiratory stimulation → hyperventilation → ↓ PaCO₂.

5. Metabolic Alkalosis

The primary abnormality is:

↑↑ HCO₃⁻.

This raises:

Blood pH.

Therefore:

↑ HCO₃⁻ → ↑ pH.

6. Compensation in Metabolic Alkalosis

The respiratory system attempts to compensate through:

Hypoventilation.

This retains CO₂.

Therefore:

PaCO₂ rises slightly.

The complete pattern is:

pH → ↑ or near normal if compensated.

PaCO₂ → slight ↑.

HCO₃⁻ → ↑↑.

Again, the larger bicarbonate change represents the:

Primary metabolic abnormality.

7. Why Respiratory Compensation Is Limited

The lungs cannot compensate indefinitely by hypoventilating because excessive hypoventilation would cause:

Hypoxaemia.

Therefore respiratory compensation for metabolic alkalosis is generally limited.

8. Respiratory Acidosis

The primary abnormality is:

↑↑ PaCO₂.

This occurs because of:

Hypoventilation.

CO₂ combines with water and ultimately increases hydrogen ion concentration.

Therefore:

↑ PaCO₂ → ↑ H⁺ → ↓ pH.

9. Compensation in Respiratory Acidosis

The kidneys compensate by:

Increasing H⁺ excretion

and

Retaining/generating HCO₃⁻.

Therefore bicarbonate rises.

The pattern shown in the image is:

pH → ↓ or near normal if compensated.

PaCO₂ → ↑↑.

HCO₃⁻ → ↑.

10. Acute versus Chronic Respiratory Acidosis

This distinction is important.

In acute respiratory acidosis, renal compensation has had little time to occur.

Therefore bicarbonate rises only slightly.

A useful rule is:

Every 10 mmHg ↑ PaCO₂ → HCO₃⁻ ↑ by approximately 1 mmol/L.

In chronic respiratory acidosis, the kidneys have had several days to compensate.

Therefore bicarbonate rises more substantially:

Every 10 mmHg ↑ PaCO₂ → HCO₃⁻ ↑ by approximately 3–4 mmol/L.

This is why a patient with chronic hypercapnic COPD may have a markedly elevated PaCO₂ while the pH is relatively close to normal.

11. Respiratory Alkalosis

The primary abnormality is:

↓↓ PaCO₂.

This occurs because of:

Hyperventilation.

Excess CO₂ is eliminated from the lungs.

Therefore:

↓ PaCO₂ → ↓ H⁺ → ↑ pH.

12. Compensation in Respiratory Alkalosis

The kidneys compensate by:

Reducing bicarbonate reabsorption

and increasing:

Bicarbonate excretion.

Therefore:

HCO₃⁻ falls.

The complete pattern is:

pH → ↑ or near normal if compensated.

PaCO₂ → ↓↓.

HCO₃⁻ → slight ↓.

13. Acute versus Chronic Respiratory Alkalosis

In acute respiratory alkalosis, renal compensation is limited.

For every:

10 mmHg ↓ PaCO₂

bicarbonate falls by approximately:

2 mmol/L.

In chronic respiratory alkalosis, renal compensation becomes stronger.

For every:

10 mmHg ↓ PaCO₂

bicarbonate falls by approximately:

4–5 mmol/L.

14. Why the Image Says “N or ↓” and “N or ↑”

The image shows:

Metabolic acidosis → pH N or ↓.

Metabolic alkalosis → pH N or ↑.

Respiratory acidosis → pH N or ↓.

Respiratory alkalosis → pH N or ↑.

The “N” refers to a disorder that has undergone sufficient physiological compensation for the pH to move:

Toward the normal range.

However, an important principle is:

COMPENSATION DOES NOT OVERCORRECT THE pH.

If the pH moves beyond normal in the opposite direction, consider:

A mixed acid–base disorder.

15. How to Identify the Primary Disorder

Start with the:

pH.

If:

pH < 7.35 → acidaemia.

pH > 7.45 → alkalaemia.

Then determine whether PaCO₂ or HCO₃⁻ explains the direction of the pH.

16. Acidaemia

If the patient has:

↓ pH + ↓ HCO₃⁻

the primary disorder is:

Metabolic acidosis.

If the patient has:

↓ pH + ↑ PaCO₂

the primary disorder is:

Respiratory acidosis.

17. Alkalaemia

If the patient has:

↑ pH + ↑ HCO₃⁻

the primary disorder is:

Metabolic alkalosis.

If the patient has:

↑ pH + ↓ PaCO₂

the primary disorder is:

Respiratory alkalosis.

18. The ROME Method

A useful memory aid is:

ROME

which stands for:

Respiratory Opposite, Metabolic Equal.

19. Respiratory = Opposite

In primary respiratory disorders, pH and PaCO₂ move in:

Opposite directions.

Therefore:

↓ pH + ↑ CO₂ → Respiratory acidosis.

↑ pH + ↓ CO₂ → Respiratory alkalosis.

20. Metabolic = Equal

In primary metabolic disorders, pH and HCO₃⁻ move in the:

Same direction.

Therefore:

↓ pH + ↓ HCO₃⁻ → Metabolic acidosis.

↑ pH + ↑ HCO₃⁻ → Metabolic alkalosis.

21. Metabolic Acidosis – Note Form

Primary change:

↓↓ HCO₃⁻.

↓

↓ pH.

↓

Lungs compensate by hyperventilation.

↓

↓ PaCO₂.

Therefore:

pH ↓ | PaCO₂ ↓ | HCO₃⁻ ↓↓

22. Metabolic Alkalosis – Note Form

Primary change:

↑↑ HCO₃⁻.

↓

↑ pH.

↓

Lungs compensate by hypoventilation.

↓

Slight ↑ PaCO₂.

Therefore:

pH ↑ | PaCO₂ ↑ | HCO₃⁻ ↑↑

23. Respiratory Acidosis – Note Form

Primary change:

↓↓ Ventilation.

↓

↑↑ PaCO₂.

↓

↓ pH.

↓

Kidneys retain/generate HCO₃⁻.

Therefore:

pH ↓ | PaCO₂ ↑↑ | HCO₃⁻ ↑

24. Respiratory Alkalosis – Note Form

Primary change:

↑↑ Ventilation.

↓

↓↓ PaCO₂.

↓

↑ pH.

↓

Kidneys excrete HCO₃⁻.

Therefore:

pH ↑ | PaCO₂ ↓↓ | HCO₃⁻ ↓

25. Four Disorders – Copyable Comparison

METABOLIC ACIDOSIS

pH = ↓

PaCO₂ = ↓ due respiratory compensation

HCO₃⁻ = ↓↓ primary abnormality

METABOLIC ALKALOSIS

pH = ↑

PaCO₂ = ↑ due respiratory compensation

HCO₃⁻ = ↑↑ primary abnormality

RESPIRATORY ACIDOSIS

pH = ↓

PaCO₂ = ↑↑ primary abnormality

HCO₃⁻ = ↑ due renal compensation

RESPIRATORY ALKALOSIS

pH = ↑

PaCO₂ = ↓↓ primary abnormality

HCO₃⁻ = ↓ due renal compensation

26. Compensation Rules – Copyable Note Form

Metabolic acidosis:

Primary ↓ HCO₃⁻.

Compensation → ↓ PaCO₂.

Metabolic alkalosis:

Primary ↑ HCO₃⁻.

Compensation → ↑ PaCO₂.

Respiratory acidosis:

Primary ↑ PaCO₂.

Compensation → ↑ HCO₃⁻.

Respiratory alkalosis:

Primary ↓ PaCO₂.

Compensation → ↓ HCO₃⁻.

Key Clinical Pattern

The easiest way to remember the entire image is:

METABOLIC = HCO₃⁻ IS THE PRIMARY CHANGE.

RESPIRATORY = PaCO₂ IS THE PRIMARY CHANGE.

Then:

ACIDOSIS → pH tends ↓.

ALKALOSIS → pH tends ↑.

And remember ROME:

Respiratory Opposite

Metabolic Equal.

So:

↓ pH + ↓ HCO₃⁻ → METABOLIC ACIDOSIS.

↑ pH + ↑ HCO₃⁻ → METABOLIC ALKALOSIS.

↓ pH + ↑ PaCO₂ → RESPIRATORY ACIDOSIS.

↑ pH + ↓ PaCO₂ → RESPIRATORY ALKALOSIS.

Medicine – Metabolic Acidosis

Metabolic acidosis is an acid–base disorder in which there is a primary reduction in serum bicarbonate (HCO₃⁻), resulting from either loss of bicarbonate, accumulation of acid, or impaired renal acid excretion.

The typical blood-gas pattern is:

↓ pH + ↓ HCO₃⁻.

The respiratory system compensates by increasing ventilation, which lowers:

PaCO₂.

Therefore:

METABOLIC ACIDOSIS → HYPERVENTILATION → ↓ PaCO₂.

1. Classification of Metabolic Acidosis

A useful first step is to calculate the:

Anion gap – AG.

The anion gap helps determine whether the fall in bicarbonate has been replaced predominantly by chloride or whether unmeasured acids have accumulated.

2. Anion Gap

The usual calculation is:

Anion gap = Na⁺ − (Cl⁻ + HCO₃⁻).

Potassium is usually omitted from the calculation.

The exact normal range depends on the laboratory, but a commonly used reference is approximately:

8–12 mmol/L.

Therefore metabolic acidosis can be divided into:

Normal anion gap metabolic acidosis

and

High anion gap metabolic acidosis.

3. Normal Anion Gap Metabolic Acidosis

In normal anion gap metabolic acidosis – NAGMA, bicarbonate falls but chloride rises to maintain electrical neutrality.

Therefore it is also called:

Hyperchloraemic metabolic acidosis.

The basic pattern is:

↓ HCO₃⁻ + ↑ Cl⁻ → normal anion gap.

4. Main Mechanisms of Normal Anion Gap Acidosis

The major mechanisms are:

Loss of bicarbonate from the gastrointestinal tract.

Loss of bicarbonate through the kidneys.

Failure of renal hydrogen-ion excretion.

Important causes include:

Diarrhoea.

Renal tubular acidosis.

Acetazolamide.

Adrenal insufficiency, particularly through type 4 RTA physiology.

5. Diarrhoea

The original notes correctly identify:

Diarrhoea

as an important cause of normal anion gap metabolic acidosis.

Intestinal secretions contain significant amounts of:

Bicarbonate.

Prolonged or severe diarrhoea causes bicarbonate loss in stool.

Therefore:

DIARRHOEA → GI HCO₃⁻ LOSS → ↓ HCO₃⁻ → HYPERCHLOREEMIC METABOLIC ACIDOSIS.

6. Diarrhoea and Potassium

Diarrhoea can also cause gastrointestinal loss of:

Potassium.

Therefore the patient may develop:

Hypokalaemia

together with:

Normal anion gap metabolic acidosis.

This can help distinguish diarrhoeal bicarbonate loss from some forms of renal tubular acidosis, particularly type 4 RTA, which causes hyperkalaemia.

7. Renal Tubular Acidosis

Renal tubular acidosis – RTA refers to disorders in which the renal tubules fail to handle acid or bicarbonate normally despite relatively preserved glomerular function, particularly early in the disease.

The characteristic acid–base disturbance is:

Normal anion gap metabolic acidosis.

8. Type 1 – Distal RTA

In type 1 distal RTA, the distal nephron cannot adequately secrete:

Hydrogen ions.

Therefore the kidney cannot acidify the urine appropriately.

The result is:

Metabolic acidosis.

9. Features of Distal RTA

Typical features include:

Normal anion gap metabolic acidosis.

Hypokalaemia.

Inappropriately high urine pH, classically above about 5.5 during systemic acidosis.

Nephrolithiasis.

Nephrocalcinosis.

The stone tendency occurs partly because of alkaline urine and:

Hypocitraturia.

10. Causes of Distal RTA

Important associations include:

Sjögren syndrome.

Other autoimmune disorders.

Certain drugs and toxins.

Inherited tubular defects.

A useful association is:

DISTAL RTA → HYPOKALAEMIA + ALKALINE URINE + RENAL STONES.

11. Type 2 – Proximal RTA

In type 2 proximal RTA, the proximal tubule cannot reabsorb bicarbonate normally.

Therefore excessive bicarbonate is lost in:

Urine.

This causes:

Normal anion gap metabolic acidosis.

12. Proximal RTA and Fanconi Syndrome

Proximal RTA may occur as part of:

Fanconi syndrome.

Generalised proximal tubular dysfunction may produce:

Bicarbonaturia.

Glucosuria despite normal plasma glucose.

Phosphaturia.

Aminoaciduria.

Uricosuria.

Therefore:

FANCONI SYNDROME → MULTIPLE PROXIMAL TUBULAR LOSSES.

13. Type 4 RTA

Type 4 RTA is particularly important because, unlike most other RTAs, it is associated with:

Hyperkalaemia.

The underlying problem is usually:

Aldosterone deficiency

or

Resistance to aldosterone.

14. Type 4 RTA Mechanism

Reduced aldosterone activity decreases distal:

Potassium secretion

and impairs effective renal acid excretion, including through effects on ammonium generation and excretion.

Therefore:

↓ ALDOSTERONE EFFECT → ↑ K⁺ + IMPAIRED ACID EXCRETION → METABOLIC ACIDOSIS.

15. Addison’s Disease

The original notes include:

Addison’s disease.

This association is correct, but the mechanism is better understood as:

Primary adrenal insufficiency → aldosterone deficiency → type 4 RTA physiology.

Therefore the characteristic combination can be:

Hyperkalaemia + normal anion gap metabolic acidosis.

16. Important Clarification About Addison’s Disease

Addison’s disease does not primarily cause acidosis by directly losing bicarbonate.

Instead:

Aldosterone deficiency → impaired distal K⁺ and H⁺ handling → hyperkalaemic metabolic acidosis.

Other features of primary adrenal insufficiency may include:

Hypotension.

Hyponatraemia.

Hyperkalaemia.

Hyperpigmentation.

17. Acetazolamide

Acetazolamide inhibits:

Carbonic anhydrase.

It acts predominantly in the:

Proximal tubule.

This reduces bicarbonate reabsorption.

Therefore more bicarbonate is lost in urine.

18. Acetazolamide and Acidosis

The sequence is:

Acetazolamide → carbonic anhydrase inhibition → ↓ proximal HCO₃⁻ reabsorption → bicarbonaturia → metabolic acidosis.

The resulting pattern is typically:

Normal anion gap hyperchloraemic metabolic acidosis.

19. High Anion Gap Metabolic Acidosis

In high anion gap metabolic acidosis – HAGMA, additional acids accumulate in the blood.

Their hydrogen ions consume bicarbonate, while their negatively charged conjugate bases remain as:

Unmeasured anions.

Therefore:

↓ HCO₃⁻ + accumulation of unmeasured anions → ↑ anion gap.

20. Important Causes of High Anion Gap Acidosis

The original notes correctly include:

Diabetic ketoacidosis.

Lactic acidosis.

Kidney failure.

Salicylate poisoning.

Methanol poisoning.

Ethylene glycol poisoning.

Additional important causes include other forms of:

Ketoacidosis

and selected:

Drug/toxin-related acidoses.

21. Diabetic Ketoacidosis

Diabetic ketoacidosis – DKA is a classic cause of high anion gap metabolic acidosis.

Severe insulin deficiency causes increased:

Lipolysis.

Free fatty acids are transported to the liver and converted into:

Ketone bodies.

22. Ketone Bodies

Important ketone bodies include:

β-hydroxybutyrate.

Acetoacetate.

Their accumulation produces:

High anion gap metabolic acidosis.

Therefore:

INSULIN DEFICIENCY → LIPOLYSIS → KETONE PRODUCTION → HAGMA.

23. Clinical Features of DKA

Typical features include:

Polyuria.

Polydipsia.

Dehydration.

Nausea and vomiting.

Abdominal pain.

Kussmaul breathing.

Altered consciousness in severe disease.

A fruity or acetone-like breath odour may occur.

24. Kussmaul Respiration

The body attempts to compensate for metabolic acidosis by increasing ventilation.

Severe metabolic acidosis can therefore produce:

Deep, rapid breathing – Kussmaul respiration.

This removes CO₂ and partially compensates for the fall in pH.

Therefore:

METABOLIC ACIDOSIS → HYPERVENTILATION → ↓ PaCO₂.

25. Lactic Acidosis

Lactic acidosis occurs when lactate production exceeds its metabolism and clearance.

It is another major cause of:

High anion gap metabolic acidosis.

26. Tissue Hypoperfusion and Lactate

A common mechanism is inadequate tissue oxygen delivery or utilisation associated with severe illness.

Important causes include:

Shock.

Sepsis.

Severe hypoxaemia.

Cardiac arrest.

Severe circulatory failure.

These can increase lactate production.

27. Other Causes of Lactic Acidosis

Lactate may also rise with:

Generalised seizures.

Extreme exercise.

Certain drugs or toxins.

Severe liver dysfunction, particularly when lactate clearance is impaired.

Therefore not every raised lactate means that tissue hypoxia is the sole mechanism.

28. Kidney Failure

The kidneys normally remove the daily non-volatile acid load and regenerate bicarbonate.

With advanced kidney failure, there is reduced excretion of acids such as:

Sulphate.

Phosphate.

Organic anions.

These accumulate in the circulation.

29. Kidney Failure and the Anion Gap

Advanced kidney failure can therefore cause:

High anion gap metabolic acidosis.

However, earlier CKD can sometimes produce a:

Normal anion gap metabolic acidosis

before substantial accumulation of unmeasured anions develops.

So the acid–base pattern can change with disease severity.

30. Salicylate Poisoning

Salicylate poisoning is especially important because it commonly produces a:

Mixed acid–base disorder.

Initially, salicylates directly stimulate the medullary respiratory centre.

This causes:

Hyperventilation → ↓ PaCO₂ → respiratory alkalosis.

31. Salicylates and Metabolic Acidosis

Salicylates also cause accumulation of organic acids and interfere with cellular metabolism.

Therefore later or significant poisoning produces:

High anion gap metabolic acidosis.

The classic pattern is therefore:

RESPIRATORY ALKALOSIS + HIGH ANION GAP METABOLIC ACIDOSIS.

This combination is highly important in examinations.

32. Methanol Poisoning

Methanol itself is not responsible for most of the severe toxicity.

It is metabolised to:

Formaldehyde

and then:

Formic acid/formate.

Formate causes severe:

High anion gap metabolic acidosis

and particularly damages the:

Optic nervous system.

33. Clinical Features of Methanol Poisoning

Features may include:

Headache.

Nausea and vomiting.

Abdominal symptoms.

Visual disturbance.

Blurred or “snowfield” vision.

Severe metabolic acidosis.

Reduced consciousness.

Therefore:

HAGMA + VISUAL DISTURBANCE → THINK METHANOL.

34. Ethylene Glycol Poisoning

Ethylene glycol is metabolised into toxic organic acids, including metabolites that ultimately promote formation of:

Calcium oxalate.

This causes:

High anion gap metabolic acidosis

and can produce:

Acute kidney injury.

35. Calcium Oxalate Crystals

Calcium oxalate crystals may appear in the urine.

They may have:

Envelope-shaped

or other characteristic appearances depending on crystal form.

Hypocalcaemia can also occur because calcium binds oxalate.

Therefore:

HAGMA + AKI + CALCIUM OXALATE CRYSTALS → THINK ETHYLENE GLYCOL.

36. Other Forms of Ketoacidosis

Not all ketoacidosis is diabetic.

Other important causes include:

Alcoholic ketoacidosis.

Starvation ketoacidosis.

These can also produce:

High anion gap metabolic acidosis.

37. Modern Mnemonic for High Anion Gap Acidosis

An older mnemonic is:

MUDPILES.

A more modern mnemonic is:

GOLD MARK.

This represents important causes of high anion gap metabolic acidosis:

G – Glycols, such as ethylene glycol and propylene glycol.

O – Oxoproline, associated with chronic paracetamol exposure in susceptible patients.

L – L-lactate.

D – D-lactate.

M – Methanol.

A – Aspirin, meaning salicylates.

R – Renal failure.

K – Ketoacidosis.

38. Normal Anion Gap – Note Form

Diarrhoea:

GI bicarbonate loss.

↓

↓ HCO₃⁻.

↓

Compensatory ↑ Cl⁻.

↓

Normal anion gap metabolic acidosis.

Renal tubular acidosis:

Abnormal renal H⁺ secretion or HCO₃⁻ handling.

↓

Normal anion gap metabolic acidosis.

Acetazolamide:

Carbonic anhydrase inhibition.

↓

↓ proximal bicarbonate reabsorption.

↓

Bicarbonaturia.

↓

Normal anion gap metabolic acidosis.

Addison’s disease:

↓ Aldosterone.

↓

↓ K⁺ secretion + impaired renal acid excretion.

↓

Hyperkalaemia + normal anion gap metabolic acidosis.

39. High Anion Gap – Note Form

DKA:

Insulin deficiency.

↓

Ketone accumulation.

↓

High anion gap metabolic acidosis.

Lactic acidosis:

Lactate accumulation.

↓

High anion gap metabolic acidosis.

Advanced kidney failure:

Reduced acid excretion.

↓

Retention of sulphate/phosphate/organic anions.

↓

High anion gap metabolic acidosis.

Salicylates:

Respiratory-centre stimulation + organic acid accumulation.

↓

Respiratory alkalosis + HAGMA.

Methanol:

Formate accumulation.

↓

HAGMA + visual toxicity.

Ethylene glycol:

Toxic acid metabolites + oxalate.

↓

HAGMA + AKI ± hypocalcaemia/calcium oxalate crystals.

40. Important Corrections and Clarifications

The original classification is broadly correct, but:

Addison’s disease is not primarily a direct bicarbonate-loss disorder.

It causes metabolic acidosis mainly because:

ALDOSTERONE DEFICIENCY → TYPE 4 RTA PHYSIOLOGY → IMPAIRED RENAL ACID EXCRETION + HYPERKALAEMIA.

Renal failure is classically associated with high anion gap acidosis when advanced, but earlier kidney disease may produce:

Normal anion gap acidosis.

Salicylate poisoning should not be thought of as simply metabolic acidosis.

The classic acid–base abnormality is:

RESPIRATORY ALKALOSIS + HIGH ANION GAP METABOLIC ACIDOSIS.

Key Clinical Pattern

METABOLIC ACIDOSIS = ↓ pH + ↓ HCO₃⁻.

For rapid recall:

NORMAL ANION GAP = BICARBONATE LOST OR RENAL ACID EXCRETION IMPAIRED.

DIARRHOEA → HCO₃⁻ LOSS.

RTA → RENAL ACID/BASE HANDLING DEFECT.

ACETAZOLAMIDE → HCO₃⁻ LOSS.

ADDISON’S → TYPE 4 RTA + HYPERKALAEMIA.

HIGH ANION GAP = EXTRA UNMEASURED ACIDS HAVE ACCUMULATED.

DKA → KETONES.

LACTIC ACIDOSIS → LACTATE.

RENAL FAILURE → RETAINED ACIDS.

SALICYLATES → MIXED RESPIRATORY ALKALOSIS + HAGMA.

METHANOL → HAGMA + VISUAL DAMAGE.

ETHYLENE GLYCOL → HAGMA + AKI + CALCIUM OXALATE.

The simplest examination rule is:

LOW HCO₃⁻ → CALCULATE THE ANION GAP → NORMAL GAP: THINK BICARBONATE LOSS/RTA; HIGH GAP: THINK ACCUMULATED ORGANIC OR RETAINED ACIDS.